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Since the first patient affected by Alzheimer’s disease was reported in 1907, it became 
the worldwide leading cause of dementia. The disease is characterised by an initial 
accumulation of amyloid plaques, neurofibrillary tangles, along with cholinergic 
markers depletion. The currently available therapies for Alzheimer’s disease provide 
an amelioration of the cognitive symptomatology for a limited period, without altering 
the disease progression and outcome. Thus, a number of research projects are currently 
underway in order to find a therapy able to modify the disease course. For this, we 
evaluated the efficacy of different acetylcholinesterase inhibitors (XJP-1, SAD-2, 
SAD-6, and FAD), along with a dual acetylcholinesterase/Glycogen synthase kinase 3 
β (16g), as potential Alzheimer’s disease treatment.  
To assess the efficacy of novel compounds we exploited two different Alzheimer’s 
models: Drosophila melanogaster, expressing either toxic amyloid peptides or 
hyperphosphorylated Tau protein, and differentiated SH-SY5Y cells treated with 
glyceraldehyde to induce Tau abnormal phosphorylation.  
The initial investigation on Drosophila Alzheimer’s models, carried out on XJP-1 
only, showed contradictive results, proving beneficial effects, on both 
symptomatology and protein deposition, in fruit flies expressing amyloid peptides, but 
not in those flies presenting an hyperphosphorylated Tau protein.  
Subsequent testing of the novel cholinesterase inhibitors on differentiated SH-SY5Y 
model presenting an hyperphosphorylated Tau protein confirmed a not homogenous 
response to this class of compounds, in any of the assessed parameters, despite a 
similar level of inhibition of acetylcholinesterase enzyme.  
Conversely, inhibition of both AChE and GSK3-β enzymes resulted in an overall 
improvement of the GA induced defects. In particular, phosphorylation levels on 
 
residues S199 and S396 of Tau protein were reduced following 16g administration. 
Other than that, 16g administration rescued the neuronal-like morphology and 
prevented neuronal cell death in this particular model, which are fundamental 
parameters when treating Alzheimer’s disease. In summary, this work shows that the 
limited beneficial effects of cholinesterase inhibition for Alzheimer’s treatment, 
mainly on the amyloid-derived pathology, can be enhanced by dual-inhibition of both 
AChE and GSK3 β, which resulted in a significant improvement of the 




Alzheimer’s disease (AD) is a protein-conformational disease (PCD), characterised by 
a severe progressive neurodegeneration, accumulation of amyloid plaques, and 
presence of neurofibrillary tangles (NFTs) (Tiwari et al. 2019). 
AD is currently recognized as the worldwide leading cause of dementia in elderly 
people, with about 6 million patients reported in the United States, with this figures 
expected to be at least doubled by 2050 (Association 2019). 
The disease is characterised by an array of cognitive symptoms, such as memory 
impairment, learning disabilities, behavioural changes, which lead to a progressive 
loss of independency in routinely tasks by the affected patients (Merriam et al. 1988). 
In addition to this, the poor efficacy of the currently available to therapies, results in 




A missing triggering mechanism, the lack of an early diagnosis biomarker, along with 
an effective therapy yet to be discovered, turned AD into the fifth cause of death 
(Heron 2019). Thus, the development of an AD therapy, able to modify the course of 
the disease is a crucial step to improve patients’ life, and the socioeconomic burden 
experienced by their families and carers.  
 
1.1 History of AD 
AD was firstly described by Alois Alzheimer in 1907, in Munich, after an autopsy on 
a 55-year-old woman named Auguste Deter, who died after a progressive cognitive 
disorder. Alzheimer was able to highlight the presence of two different pathologies in 
the woman’s brain: abnormal intercellular aggregates and the presence of miliary foci 
surrounded by a special substance in the cortex (Alzheimer 1907; Stelzmann et al. 
1995). The special substance was later characterized in 1984 by Glenner and Wong to 
be a 4.2kDa peptide formed of 40-42 amino acids (Glenner et al. 1984). They also 
speculated that this peptide was originated from the cleavage of a longer precursor, 
which was then identified in 1987, and subsequently named Amyloid Precursor 
Protein (APP), while their peptide is now known as amyloid-β peptide (Aβ peptide) 
(Kang et al. 1987). 
On the other hand, the intercellular aggregates were later shown to be formed of 
hyperphosphorylated and shorter forms of the microtubule associated protein (MAP) 
Tau (Goedert et al. 1988).  
Through the years, a number of different AD triggering mechanisms have been 
suggested, but none of them was clearly demonstrated. However, familial forms, with 
an early onset of Alzheimer’s disease (EOAD), are characterised by the presence of 
different mutations in crucial genes. Genetic screenings have identified a number of 
 
mutation in genes, such as APP, PSEN1, and PSEN2. Patients with an EOAD, present 
a clear pathogenic mechanisms, often derived by the accumulation of Aβ peptides, as 
it happens in cases presenting the Arctic mutation of the APP gene. The latter is a 
substitution of the glutamate on residue 693 with a glycine, which in turn leads to the 
formation of toxic 42aa long Aβ peptides (Kamino et al. 1992).  
Despite EOAD have a clear etiopathogenesis of AD, they account for only 1% of the 
total patients. Thus, the vast majority of patients are affected by a late-onset 
Alzheimer’s disease (LOAD), which main risk factor is aging (Sala Frigerio et al. 
2019). However, several causative agents have been proposed, such as amyloid 
cascade, NFTs formation, and the cholinergic hypothesis. 
 
1.2 Alzheimer’s disease fundamental features 
1.2.1 Amyloid Precursor Protein 
APP is a single pass transmembrane glycoprotein with a large extracellular domain, 
and it plays a role in cell motility, neurite growth and cell survival (Oh et al. 2009). In 
Neurons APP is found in the axon and somatodentric areas, and its functions are 
implicated in multiple pathways. Its role in cell signalling it can be divided into two 
categories: interactions with APP family members or interactions with other receptors 
(Müller et al. 2017). In the first scenario  two APP proteins from two neurons interact 
together (trans-dimer), they promote synaptogenesis, and synapsis stability 
(Baumkötter et al. 2012).  When two APP of same cell form a dimer (cis-dimer) they 
promote APP processing. When a sAPPα interact with an APP in the membrane, they 
promote cell survival and neuroprotection (Isbert et al. 2012). In interaction with other 




APP can also have a receptor-like role in multiple pathways. In neurite outgrowth, 
membrane APP co-localize with FE65, which in turn activates RAC1. This enzyme is 
able to regulate actin dynamics and, therefore, drive morphological changes (Müller 
et al. 2017). 
 
1.2.2 Amyloid plaques 
The amyloid cascade hypothesis gives to amyloid plaques deposition a central role in 
AD pathogenesis (Selkoe 1991).  
It is during the APP processing where the Aβ peptides formation takes place. However, 
APP proteolysis can follow multiple different pathways and not all of them lead to the 
production of Aβ peptides. The most important steps of APP proteolysis occur at the 
cell surface and in the Trans-Golgi-Network (TGN). In a process mediated by clathrin-
associated vesicles, APP can be transported from the TGN either to the cell surface or 
to an endosomal compartment. On the cell surface APP can undergo to a series of 
cleavages, mediated by α-secretase first, and γ-secretase then, which do not generate 
β amyloid peptides, but generates soluble ectodomain APPα (sAPPα) instead (also 
known as non-amyloidogenic pathway) (O'Brien et al. 2011). Conversely, in the 
amyloidogenic pathway APP from the TGN can be directed to an endosomal 
compartment containing the β-site amyloid precursor protein cleaving enzyme 1 
(BACE1, also known as β-secretase). The latter cleaves APP, between +1 and +11, 
releasing the sAPPβ ectodomain, while the APP C-terminal fragment becomes 
substrate of the endosomal γ-secretase, which cleaves it in a number of sites from +40 
to +44, generating β-peptides of different length, with Aβ-40 and Aβ-42 being the most 
commonly produced (Nalivaeva et al. 2013).  
 
The lack of sAPPα, which promotes neurite growth and neurite plasticity, can result in 
toxic effect, playing a role in AD pathogenesis as well (Gralle et al. 2009).  
However, the accumulation of Aβ peptides exert the most toxic effect in AD 
pathogenesis. In particular, the Aβ peptides aggregates have the most cytotoxic effect, 
which results in the activation of oxidative stress pathway, aberrant activation of 
kinases, most likely resulting in neuronal cell-death (Leong et al. 2020).  
Aβ peptides increase the expression of DKK1, and LRP6 inhibitor, therefore impairing 
the Wnt-signalling and further shifting the APP processing towards the amyloidogenic 
pathway, and establishing a pathological positive-feedback loop(Norwitz et al. 2019). 
Morevoer, GSK3β also phosphorylates Tau protein on multiple residues, causing Tau 
dissociation from the microtubules, causing cytoskeletal defects, impaired axonal 
transport, and aggregation of the protein Tau into NFTs, which are known to be 
neurotoxic (Llorens-Martín et al. 2014).  
In addition to this, mutation in APP protein, such as the Arctic mutation, result in a 
higher aggregation rate of Aβ monomers, into aggregates first, in Aβ protofibrils then, 
and finally into amyloid plaques (Johansson et al. 2006). Furthermore, Aβ protofibrils 
have proven to be synaptotoxic, therefore damaging the neuronal connectivity 
(O'Nuallain et al. 2010).   
According to the amyloid hypothesis, the accumulation of Aβ peptides results in an 
improper activation of kinases, such as Glycogen synthase kinase 3 beta (GSK3-β), 
which then increase the phosphorylation levels of the Tau protein, ultimately resulting 
in the formation of NFTs, the other fundamental hallmark of AD (Hardy et al. 1992; 




1.2.3 Tau protein 
Tau is a microtubule-associated protein (MAP) that exists in 6 different isoforms in 
the human brain which are all generated from alternative splicing of the same pre-
mRNA (Himmler et al. 1989; Goedert et al. 1989).   
Each of the six isoforms differs in the number of microtubule binding sites at the 
carboxyl terminal half (three or four sites named 3R and 4R respectively) and in the 
number of amino terminal inserts: one (1N), two (2N) and zero (0N). As a result, the 
alternative splicing generates 3 different forms of 3R Taus (0N3R, 1N3R and 2N3R) 
and 3 different forms of 4R Taus (0N4R, 1N4R and 2N4R) with the isoform 2N4R 
being the largest in size in human brain (Götz et al. 2019). 
The distribution of different Tau isoform is developmentally controlled, with Tau 
isoforms -3R and -4R having a 1:1 ratio in adults’ neurons (Götz et al. 2019).   
Tau functions are multiple, from stabilization of the microtubule architecture, to 
axonal transport, neuronal polarity, and axon stability (Ittner et al. 2011; Dubey et al. 
2008; Goedert et al. 1990).  
In the neurons Tau can be either associated to the microtubule or to the membrane. 
Phosphorylated Tau is mainly present in the somatodentric area, whilts 
dephosphorylated Tau is mainly present in the axon terminal (Avila et al. 2004). Tau 
main function is tubuline stabilization in microtubule architecture. It also promotes 
neurite outgrowth, as seen in non-neuronal cells where its ectopic expression resulted 
in the formation of long cytoplasmatic extension (Weingarten et al. 1975). In addition 
to this, it is proposed a role for Tau in axonal transport since its microtubule binding 
domain overlaps with the molecular motor kinesis (Combs et al. 2019).  
Tau protein also play a role in synapsis stabilization and long term potentiation (LTP). 
Tau protein is translocated from the dendritic shaft to the synaptic compartment, upon 
 
synapsis activation. At the same time, kinase Fyn, in the synaptic compartment, 
phosphorylate NMDAr to facilitate NMADR and PSD-95 interaction, which is crucial 
for a proper LTP (Frandemiche et al. 2014). The de-association of the Tau/Fyn/PSD-
95/NMDAr complex is equally important to maintain proper stabilization of NMDAr 
and correct LTP, which is disrupted in AD pathology (Marttinen et al. 2018).  
 
 
1.2.4 Neurofibrillary tangles 
NFTs are found in the neuronal cytoplasm of AD patients, and are composed of 
abnormally phosphorylated Tau protein. In addition to this, Tau protein can be subject 
to a number of different post-translational modifications, with the majority of them 
having a physiological function. However, abnormal phosphorylation of Tau protein 
can results in a loss of affinity toward tubulin, resulting in a jeopardized microtubule 
architecture (Martin et al. 2011).   
A total of 85 residues can be subject of phosphorylation on Tau isoform 2N4R, 
resulting in either physiological, or pathological, effects (Tapia-Rojas et al. 2019). In 
particular, Serine (S) 199 and S396 residues, were found to be hyperphosphorylated in 
AD mice models (Foidl et al. 2018). Whilst, Threonine (T) 205 phosphorylation was 
found to have protective effects, against Aβ peptides-induced toxicity (Ittner et al. 
2016). 
Tau hyperphosphorylation is the result of the aberrant activation of either kinases, or 
phosphatases enzymes.  One of the most studies kinase, responsible of phosphorylation 
on Tau protein at multiple residues, is GSK3-β.  
GSK3-β is ubiquitously expressed in the central nervous system (CNS), and is 
activated by a number of different pathways, which are often linked to AD (Beaulieu 
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2012; Chu et al. 2017; Hernandez et al. 2013; Hooper et al. 2008; Li, Lv, et al. 2012b). 
Moreover, phosphorylation performed by GSK3-β on Tau results in a loss of affinity 
to microtubules and promotion of Tau self-aggregation (Jackson et al. 2002; 
Hernández et al. 2010).  
In AD, as well as in other tauopathies, the aberrant phosphorylation process that occurs 
on Tau triggers its assembly in paired helical filaments (PHF) and straight filaments 
(SF) which leads to the development of NFTs (Farias et al. 2011). 
AD is considered a secondary tauopathy, due to the contemporaneous presence of 
NFTs and amyloid plaques, and it is well known the strict link between these two 
fundamental hallmarks of AD (Götz et al. 2019).  
Studies in mice have demonstrated that, Aβ increases the NFTs presence in the 
surrounding areas of the brain. Moreover, it was shown that hyperphosphorylated Tau 
is required to trigger amyloid toxicity in vivo, with prevention of cognitive defects, 
neuronal death, synaptotoxicity, along with reduction of mortality, in Tau knockout 
mice despite the presence of amyloid plaques (Roberson et al. 2007; Leroy et al. 2012). 
Tau phosphorylation is a major issue when treating AD, the lack of a clear triggering 
mechanism, and the multiple toxic effect because of Tau aberrant phosphorylation 
make this challenge even more difficult. Evidence about the involvement of the 
cholinergic network in Tau phosphorylation, along with beneficial effects of the 
cholinergic replacement therapy, were not confirmed in patients, leaving space for an 
unmet clinical target (Hampel et al. 2018; Noh et al. 2009; Yoshiyama et al. 2010; 
Tayeb et al. 2012).  
 
 
1.2.5 Cholinergic network 
The cholinergic network is well known to play a role in cognitive functions, forming 
those crucial connections implicated in the memory and learning abilities (Hampel et 
al. 2018). The number of different cholinergic pathways mainly depends on the type 
of acetylcholine receptor expressed by the examined neuron. In the human brain, 
acetylcholine binds to two different categories of receptor: nicotinic or muscarinic.  
The nicotinic receptors are an ion channel heteropentamer, composed of two alpha 
subunit, one delta, one gamma and one beta subunit. The receptor structure can be 
found in two status, closed or open, and the shift from a closed status to an open status 
depends on the binding of acetylcholine (or other agonists)(Albuquerque et al. 2009). 
In addition to this, the composition of the nicotinic receptor is complicated by the 
presence of different types of alpha subunits, known as alpha-like, which further 
differentiate the properties of the nicotinic receptor (Albuquerque et al. 2009).  
The stoichiometry of the different subunits characterize the receptor subtypes. The α7 
nicotinic receptor can be activated by both acetylcholine and choline, and it is 
permeable to both Na+ and Ca2+ ions. Conversely, the α2β4 and α3β4 receptors are 
only activated by acetylcholine, and are only permeable to Na+. This differences in 
permeability and ligand affinity confer the various receptor subtypes the ability, or not, 
to generate action potential by themselves, as it happens for the α2β4 and α3β4 
receptors, without needing the activation of other receptors (i.e. NMDA receptors) 
(Khiroug et al. 2002). The location of the nicotinic receptor further influence their 
function in the human brain. Pre-terminal α2β4 and α3β4 receptors located in the CA1 
interneurons in the hippocampus, one of the most affected brain areas in AD, regulate 
GABA release and, therefore, inhibitory signalling toward the postsynaptic neurons. 
The presence of α4β2 in myelinated axons has been shown to modulate axon 
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excitability and LTP. α7 nicotinic receptor found in the somatodentric area of neurons 
are responsible of Ca2+  currents, which is required for neuron desensitization, 
especially in hippocampal GABA neurons (Albuquerque et al. 2009).  
Differently from the nicotinic receptors, the muscarinic receptors is a class of G-
coupled receptors. Five different subtypes of this class of Ach receptors exists, M1-
M5, with the M1 making up 60-90% in the human brain. This subtype is of peculiar 
important as upon Ach binding, it activates the PKC, which in turn phosphorylates 
GSK3-β, therefore inactivating it, preventing potential Tau phosphorylation (Jiang et 
al. 2014) .  
 
1.2.6 Cholinergic system in AD pathogenesis 
The mechanisms underlying AD pathogenesis are multiple, and the connection among 
them not yet fully understood. These include amyloid deposition, NFTs, 
neuroinflammation, insulin resistance, and depletion of cholinergic markers 
accompanied by a loss of cholinergic neurons.   
In particular, the cholinergic system attracted the attention after multiple reports 
regarding its involvement in cognitive networks, and the severe neurodegeneration of 
cholinergic neurons during AD progression (Whitehouse et al. 1981). Despite the 
cholinergic hypothesis, which place the cholinergic lesion as central triggering 
mechanism, is not fully demonstrated and accepted, the involvement of the cholinergic 
network on multiple pathways involved in AD progression, and symptoms 
exacerbation is clear. The cholinergic depletion seen in AD patients is typically pre-
synaptic, with the axons of the neurons projecting from the Nucleus basalis of Meynert  
(NBM) to the cortex undergoing a severe neurodegeneration (Hampel et al. 2018).  In 
addition to this, the post-synaptic neurons present changes in acetylcholine receptors 
 
during AD progression, with either muscarinic and nicotinic receptors being less 
expressed or dysfunctional (Schröder et al. 1991; Jiang et al. 2014b). This is of great 
relevance, since different subtypes of acetylcholine receptors can have a role in AD 
pathogenic pathways. In particular, α7 nicotinic receptor activation result in a 
downregulation of GSK3-β enzyme, which is responsible of Tau abnormal 
phosphorylation and shifting APP processing towards the amyloidogenic pathway 
(Beaulieu 2012) (Hooper et al. 2008; Chu et al. 2017). Moreover, activation of α7 
receptor, result in a reduced neuroinflammation, which plays an important role in 
neuronal damage during AD (Kalkman et al. 2016).  
Nicotinic α2β4, the major component of nicotinic receptors, is also severely depleted 
in AD brain. This is of particular relevance given its function in GABA release, which 
suggests a possible role for cholinergic depletion in excitotoxicity observed in AD 
brains (Albuquerque et al. 2009).  
In addition to this, activation of muscarinic receptors were reported to shift the APP 
processing towards the non-amyloidogenic pathway (Cisse et al. 2011; Welt et al. 
2015). Activation of M1 muscarinic receptor inhibits GSK3-β via PKC pathway. 
Depletion of ACh, as observed in AD patients results in reduced activation of M1 
receptor, and subsequent over-activation of GSK3-β, which not only phosphorylates 
Tau protein, but also shift APP process towards amyloidogenic cleavage by 
phosphorylating APP protein. Moreover, activation of M1 receptors, stabilizes beta-
catenin, by inhibition of GSK3-β, and induces the expression of engrailed and Cyclin-
D1 genes (involved in cell survival processes). In AD, it has been found that patients 
present uncoupled G-protein from muscarinic receptor M1. It is suggested that amyloid 
peptides may induce such uncoupling, activating a further mechanism to increase 
amyloidogenic pathway (Norwitz et al. 2019; Jiang et al. 2014a). 
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Animal experiments, further strengthened the involvement of the cholinergic network, 
by demonstrating that cholinergic lesions, or deficit, result in amyloid deposition, Tau 
phosphorylation, and pro-inflammatory pathways activation (Ramos-Rodriguez et al. 
2013; Field et al. 2012).  
Studies on healthy patients have confirmed the role of cholinergic networks in 
cognitive processes, with anti-cholinergic therapies resulting learning and cognitive 
impairments (Sittironnarit et al. 2011). Other than that, anti-cholinergic treatment 
exacerbated cognitive symptomatology in patients at risk of AD, especially in those 
already presenting amyloid plaques (Lim et al. 2015).   
Conversely, therapies that improve cholinergic connectivity, such as 
acetylcholinesterase (AChE) inhibitors, were found to improve the cognitive functions 
in AD patients, and are now the most represented class of molecules for AD therapy 
approved by the FDA (Summers et al. 1986; Cavedo et al. 2016; Cavedo et al. 2017; 
Hampel et al. 2018). 
 
1.2.7 Neuroinflammation in AD 
In AD pathogenesis, neuroinflammation is primarly caused by microglial cells. Aβ 
peptides activate microglial cells, which in turn secrete pro-inflammatory citokines 
and chemokines . The aggregation of amyloid peptides results in a chronic activation 
of microglial cells. Chronic production of pro-inflammatory cytokines, triggers the 
assembly of the apoptosis-associated speck-like protein containing CARD (ASC 
specks) (Mandrekar-Colucci et al. 2010). The ASC specks are known to promote the 
formation amyloid plaques, prevent amyloid clearance, and promote their spreading, 
fruther aggravating the neuroinflammatory scenario (Venegas et al. 2017). In addition 
to this, microglia are well known for their role in synapsis pruning. The constant 
 
activation of microglial cells increases microglial-mediated synaptic loss, aggravating 
the neurodegeneration in AD (Heneka et al. 2015).  
TREM-2 expressing microglia have a physiological role in synapsis pruning during 
development. Multiple ligands can physiologically activate TREM-2, such as 
phospholipids, lipoprotein, phosphoglycan. In AD, TREM-2 amyloid oligomers are 
capable of activating TREM-2, which further aggravates the inflammatory status in 
the brain (Gratuze et al. 2018). 
 
1.2.8 NMDA receptors and excitotoxicity  
NMDA receptor are Ca2+ and Na+ channels, activated by the major excitatory 
neurotransmitter in the human brain, glutamate. Under physiological condition 
glutamate activates NMDAr, which in turn allows the influx of Ca2+ and Na+, 
generating depolarization and axon potential. This mechanisms is finely regulated to 
generate as LTP, a crucial mechanism for neuronal plasticity, generation of novel 
networks, memory and learning functions (RIEDEL et al. 1996).  
However, improper activation of NMDAr can lead to uncontrolled Ca2+, resulting in 
cellular toxicity by disrupting mitochondrial functioning, and therefore inhibiting 
proper metabolism (Wang et al. 2017). The stimulation of glutamate receptor induces 
changes in concentration of Ca2+, Ca2+, and H+ ions in the cells. It is suggested as well 
that other ion channels such as TRP1 may play a role in increased Ca2+ levels under 
oxidative stress and excitotoxcity conditions. In addition to this, glutamate-induced Ca 
influx activate mitochondrial PARP-1, which in turn lead to decreased NADH levels, 
resulting in profound mitochondrial depolarization, and bioenergetics failures. 
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Aβ peptides increase Long-term depression, via excitotoxicity mechanisms, as a result 
of post-synaptic NMDAr desensitization, and overstimulation of extrasynaptic 
NMDAr (Rush et al. 2014).  
 
1.3 Models to study AD 
Experimental models are a crucial tool to study the fundamental mechanistic biology 
of every disease, as well as the efficacy of potential therapies. The complexity of AD 
has frequently limited the realism of experimental models, which often resulted in 
contradictive results.  
AD models are vary, such as mice, Drosophila melanogaster, cells (either cell lines, 
or patients derived), and Caenorhabditis elegans (Drummond et al. 2017). The 
majority of them exploit the transgenic expression of either Aβ peptides, or human 
Tau, in order to study amyloid plaques derived pathology and Tau 
hyperphosphorylation respectively (Busche et al. 2019; Smith et al. 1998). However, 
different approaches have been used, such as cholinergic denervation in mice, to study 
the cognitive defects described in AD (Lim et al. 2015).  
 
Despite the large number of different models available to study AD, none of them 
represent the real scenario of a human patient. This fundamental limit often results in 
a failure during clinical trials of potential AD therapies, since the results in pre-clinical 
studies are not confirmed in patients. As a result, since 2003 the 100% of drug 
candidates for AD treatment have failed in clinical trial (Cummings et al. 2019b). 
Thus, the development of a reliable model, able to recapitulate the complexity of the 
human clinical scenario of AD, remain an open challenge.  
 
 
1.3.1 Drosophila melanogaster as model of AD 
The common fruit fly has served as model organism for many decades, to study both 
mechanisms underlying a certain phenotype, and for drug screening purposes. 
Drosophila melanogaster allows the simultaneous study of hundreds of animal 
without special adjustment to manage them. In addition to this, analysis of the fruit fly 
genome has showed that 77% of disease-causing genes in humans are present in 
Drosophila as well, therefore allowing  the study of multiple pathways linked to a 
particular disease (Reiter et al. 2001). 
However, in some diseases, such as AD, the genes related to the pathogenesis may 
harbour some differences. For instance, the APPl gene in Drosophila, orthologue of 
the APP human gene, does not present the β domain, therefore preventing any Aβ 
peptide generation. Moreover, in Drosophila dBACE1 enzyme, the equivalent of the 
human BACE1, has little to no activity raising further problems to study the human 
amyloidogenic pathway and its product Aβ peptides (Bilen et al. 2005; Nichols 2006). 
To overcome this problem, a number of research groups have exploited the UAS/Gal4 
system to drive the expression of AD human genes in the fruit fly (Duffy 2002).  
The UAS/Gal4 is a binary system composed of the Upstream activating sequence 
(UAS), which works as gene promoter, and the Gal4 protein, which binds to UAS and 
recruit the transcription machinery. By placing the gene of interested under the control 
of the UAS promoter, researcher have developed a multitude of different Drosophila 
models. The expression of the Gal4 can be spatially limited to a particular area, for 
instance CNS, to further optimize the fruit fly model (Chakraborty et al. 2011).  
Other aspects of Drosophila melanogaster have been exploited to model diseases, for 
instance the compound eye.  
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The fruit fly eye is composed of hundreds of repetitive units called ommatidia, and 
each one of them is connected to 8 photoreceptor neurons (Katz et al. 2009). The 
defined eye structure, and neuronal connection, have been used to develop the Rough 
eye phenotype (REP), in which a transgene expression is driven toward the compound 
eye (Zhong et al. 2019). The subsequent transgene expression results in a jeopardized 
morphology and a REP (Wolff et al. 1991). The REP has been extensively used to 
study AD neurodegeneration, and therapies able to prevent it (Zhong et al. 2019).  
 
In addition to a reduced lifespan as a result of AD-related gene expression, the fruit fly 
offers a number of assays to study behaviour and memory as well, and how these 
parameters are affected by the AD gene expression through a certain period (Pham et 
al. 2018). The simple climbing assay can be used to assess the locomotive functions 
of a Drosophila under different AD treatment for instance (Zhang, Li, et al. 2016). 
Also, the fruit fly memory phases can be used to study the fly cognitive functions after 
the expression of AD related genes (Chakraborty et al. 2011; Miyazaki et al. 2019).  
To date a number of different genotypes have been generated by driving the expression 
of the human APP, BACE1, and MAP genes, either alone or together. These models 
have served as drug screening platforms to study different type of therapies, such as 
plant-derived compound, peptides, and radiation (Hwang et al. 2019; Miyazaki et al. 
2019; Zhong et al. 2019).  
Thus, Drosophila melanogaster can be modelled to recapitulate the human AD 
scenario, and exploited for mechanistic and drug screening experiments. 
 
 
1.3.2 Cell culture models of AD 
Cell culture models have been developed to study different mechanisms of AD. The 
controlled environment and media gives a great advantage to point to a particular 
component the subsequent effect.  
Among different cell lines, SH-SY5Y cells, derived from bone marrow neuroblastoma, 
have been extensively exploited to study Aβ peptides induced toxicity and cell deaths, 
the mechanisms behind it, and several compounds  to prevent it (Agholme et al. 2010; 
Huang et al. 2015; Wang et al. 2009; Zhang, Yu, et al. 2010).  Moreover, SH-SY5Y 
have been used to model Tau abnormal phosphorylation either by adding chemical 
compounds, such as glyceraldehyde and okadaic acid, or by exploiting hypothermia 
(Zhang and Simpkins 2010; Bretteville et al. 2012; Koriyama et al. 2015).  
Despite the utility of using SH-SY5Y cell line as AD model, it harbours some crucial 
limitations, such as active division, poor neurite density, and poor neurite outgrowth. 
To overcome this problem, a differentiation protocol of SH-SY5Y exploiting retinoic 
acid (RA) and brain derived neurotrophic factor (BDNF) was developed to achieve 
neuronal differentiation (Agholme et al. 2010; Constantinescu et al. 2007; Shipley 
2016).  
The SH-SY5Y-derived neurons well recapitulated the human neuronal characteristics, 
with long projection neurons, a G0 phase, and high neurite density. This neuron-like 
cells have been used to study different aspects of AD (Krishtal et al. 2017).  
Despite differentiated SH-SY5Y cells offer a more realistic model of AD, they do not 
form a proper neuronal network architecture, due to the limitation of a 2D cell culture 
type. Thus, novel approaches relying of 3D cell culture have been recently developed. 
These model offer to study not only neurons in a proper, brain-like architecture, but as 
well they offer the possibility to study a complex structure such as the blood brain 
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barrier (BBB) (Choi et al. 2014; Kwak et al. 2020; Papadimitriou et al. 2018) (Shin et 
al. 2019) .  
Other cell line models used to model AD include HEK293T cells, derived from the 
human embryo kidney (Lessard et al. 2005). This type of cells has been extensively 
exploited to perform Crispr genome editing on crucial AD genes, such as BACE1, 
ADAM10, and PSN1 (Giau et al. 2018). However, the realism of a kidney cells used 
to model a complex neurodegenerative disease as AD is limited (Drummond et al. 
2017) 
In addition to this, some 3D cell culture models have exploited patient derived iPSC 
to model AD, despite some limitations due to epigenetic heterogeneity that may differ 
from patient to patient, and the fact that the subsequent neuronal differentiation result 
in a non-adult neuron (Zhang et al. 2014; Drummond et al. 2017). 
 
1.3.3 Mouse models of AD 
The generation of more complex AD models that better recapitulate the human 
scenario has mainly relied on the exploitation of mouse models. Through the year,  the 
majority of mouse models have been generated using autosomal dominant forms of 
AD.  Despite this form of AD account for a very small minority of the human patients, 
they share some similarities with sporadic AD (Hall et al. 2012).  The majority of 
genetic AD mice models express transgenic human APP, harbouring defined 
mutations, such as the Arctic, Swedish, or London (Cheng et al. 2004). These models 
showed accumulation of Aβ peptides, resulting in memory and learning deficit. In 
addition to this, they presented a characteristic synaptotoxicity, but failed to show any 
neurodegeneration, the main hallmark of AD. Moreover, this type of mouse model 
 
only presents amyloid plaques, but not NFTs another crucial aspect in AD 
pathogenesis and symptoms exacerbation (Hall et al. 2012).  
Apart from amyloid, genetic Tau mice models have also been developed. The latter 
exploit mutated forms of human Tau, which are the primary cause of fronto-temporal 
dementia. Despite recapitulating the typical Tau hyperphosphorylation, and derived 
defects, none of these mutant Tau variants has been linked to AD, posing a crucial 
limit on the validity of mice models to study AD (Hall et al. 2012).  
Other strategies to model AD in mice have exploited selective neuronal damage to 
recapitulate the cognitive dysfunction observed in the patients. The usage of 
scopolamine, a muscarinic antagonist, is used to block the cholinergic network and 
induce memory and learning defects in mice (Bhuvanendran et al. 2018)  . However, 
this method has the main limitation of affecting only the cholinergic system 
selectively, whilst human patients experience a broader and less specific neuronal 
dysfunction (Drummond et al. 2017).  
Despite a number of differences between mice AD models and the human scenario, 
they still are an efficient model for a crucial aspect of AD drug development: the 
presence of a functional BBB. This structure in drug development cannot be assessed 
in other models such as Drosophila melanogaster, C. elegans, and cell culture, 









1.4 AD therapies 
Treatment of AD and related dementias remains an open challenge for a number of 
research groups around the world. This invalidating disease not only creates 
pathological issues in the affected patients, but has social and economic consequences 
for the patients’ families as well (El-Hayek et al. 2019).  
The available therapies do not show any disease modifying effect, with a temporary 
benefit only on the psychiatric symptomatology that is soon reversed by the disease 
progression.  
So far, a number of different drug candidates have been proposed as potential AD 
therapy, but eventually failed during clinical trials. These included anti-amyloid 
agents, anti-Tau agents, monoclonal antibodies, and further psychiatric therapies 
(Cavedo et al. 2016). The lack of a proper AD model to study the drug effects, an early 
diagnosis biomarker still missing, and difficulties in recruiting patients for clinical 
tests, are the major contributors for clinical testing failures.  
Despite difficulties, the search of a therapy able to stop the progression, or at least 
delay, the disease is necessary. It is estimated that we could have 9.2 million less cases 
per year, just by delaying the disease onset of 12 months (Brookmeyer et al. 2007).  
Currently, two class of molecules are approved for AD treatment: AChE inhibitors and 
NMDAR antagonists. In addition to this, a combination of both AChE inhibitor and 
NMDAR antagonist is used in severe AD cases (Graham et al. 2017). 
Unfortunately, none of these molecules showed disease-modifying effects. Thus, 
improvement of the already available therapies or research for new drug candidates 




1.4.1 AD therapy selection 
The choice of treatment made by the clinician mainly depends on two factors: stage of 
AD, and patient compliance.   
AD progression is divided into three stages: mild, moderate, and severe, which take 
into account different psychiatric symptoms, and ability to perform daily tasks. In 
order to discriminate between different phases of AD, the clinician perform a 
psychiatric assessment, i.e. Mini-Mental state examination, during which the patient 
performance on multiple cognitive tasks are given a quantitative score. The score 
obtained on such tests will determine the AD stage of the patient (Galasko et al. 1990). 
Subsequently, the choice of the AD therapy will be based on the stage of the disease. 
Usually Rivastigmine and Glantamine are the primary choices in patients with mild to 
moderate AD, whilst severe cases of AD are routinely treated with Memantine or 
Donoepezil, or both (Buschert et al. 2010). 
Patient compliance in AD therapy selection is another aspect for clinicians, as often 
patients find difficult to get tablets, especially at multiple times during the day (i.e. 
Donepezil). For this, Rivastigmine available in patches is often a golden route for 
patient with poor compliance.  
 
1.4.2 AChE inhibitors 
AChE inhibitors are the first class of molecules approved by the Food and Drug 
Administration (FDA) in 1993, after Tacrine was cleared to be administrated to 
patients. However it was subsequently retired due to severe side-effects (Knapp et al. 
1994).  
Currently, three different AChE inhibitors are available for AD treatment: Donepezil 
(Arcipet), Galantamine (Razadyne), and Rivastigmine (Exelon) (Birks et al. 2009).  
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AChE inhibitors therapy, also known as cholinergic replacement therapy, aims to 
increase the acetylcholine levels, by inhibiting AChE enzyme, and improve the 
cholinergic connectivity, crucial in memory and learning functions.  
Soon after AD diagnosis the AChE inhibitor therapy start, with dosage increased along 
with disease progression.  
Donepezil is initially administrated at 5mg per day, and subsequently at 10mg after 
few weeks. However, 23mg dosage is available, despite increased side effects (Farlow 
et al. 2010).  
Rivastigmine is usually prescribed as 1.5mg twice a day, and increased to 6mg after 
few weeks (Birks et al. 2009).  
Galantamine therapy is initiated at 4mg twice a day, and subsequently increased to 
12mg. Despite some differences in dosages, and mechanism, none of these therapies 
resulted to have increased efficacy when compared to each other (Tayeb et al. 2012).  
Study in placebo controlled trials showed as well that improvement of the psychiatric 
symptomatology was modest, with effects lasting up to two years (Giacobini 2000; 
Hansen et al. 2008). Furthermore, none of these therapies prevented the progressive 
decline of cognitive functions in long term study (Courtney et al. 2004).  
Despite the controversy about the efficacy of AChE inhibitor therapy, it was proven 
that such molecule at least delayed the nursing home placement of AD patients of one 
year (Wattmo et al. 2011). AChE inhibitor therapy, reduced caregiver stress, and 
behavioural symptomatology (Adler et al. 2014).  
 
1.4.3 NMDAR antagonist 
The second class of molecules approved by the FDA as AD therapy is NMDAR 
antagonist. In an attempt to prevent excitotoxicity resulting from glutamate, and Tau 
 
phosphorylation, NMDAR antagonist Memantine, is currently administrated to AD 
patients (Folch et al. 2018).  
Increased levels of Aβ peptides can increase the activity of NMDAR, leading to an 
uncontrolled Ca2+ uptake, which in turn impairs the mitrocondrial functions and, 
therefore, triggering the release of reactive oxygen species (ROS) which are cytotoxic 
(Lipton 2007).  
In particular, among various NMDAR subtypes, Memantine main targets are 
extrasynaptic NMDAR, located in the dendrites, and not those located in the synapsis 
(Lipton 2005; Folch et al. 2018).  This is of peculiar importance, since extrasynaptic 
NMDAR are implicated in Aβ production and toxicity (Tackenberg et al. 2013; Rush 
et al. 2014).  
Memantine significantly ameliorated the cognitive functions of AD patients, 
administrated either alone, or as combination with AChE inhibitor (Dantoine et al. 
2006; Gauthier et al. 2008).  
Despite beneficial effects on psychiatric symptomatology, and the involvement of 
NMDAR over-activation with the pathogenesis of AD, Memantine treatment did not 
modify the progression of the disease (Tayeb et al. 2012). 
 
1.4.4 Future perspectives 
The unmet clinical need of an effective therapy to stop the disease progression on AD 
patients continue to stimulate the research of novel drug candidates. Currently, there 
are 121 drugs under clinical trial, at various phases, as potential AD therapy 
(Cummings et al. 2020). 
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In phase III of clinical trials there are 29 agents under study, with 40% of them 
targeting the psychiatric symptomatology, whilst the remaining 60% are potential 
disease-modifying pharmaceutical (Cummings et al. 2020).   
 
Therapies with disease-modifying effects exploit different targets and approaches to 
interfere with AD pathogenesis. Targeting Aβ peptides aggregation, and prevention of 
oligomer formation, by using monoclonal antibodies is a common strategy, despite a 
number of clinical trials have failed to show any significant amelioration on AD 
patients, further highlighting the raising doubts about the amyloid hypothesis (Panza 
et al. 2019).   
A different target is the neuroinflammation, which represents 20% of the clinical trial 
target of disease-modifying molecules (Cummings et al. 2020). It is clear that 
neuroinflammation plays a major role in AD pathogenesis, being the ultimate actor 
responsible of neuronal damage and death, thus its prevention, or modulation, may be 
an effect AD therapy (Heneka et al. 2015).  
 
Aberrant autophagy is a raising mechanism that could trigger AD pathogenesis, with 
an aberrant persistence of impaired mitochondria as result of deubiquitinase (DUB) 
enzyme activity. Thus, a potential therapy based on DUBs inhibitors is currently under 
investigation, not only for AD, but also for other neurodegenerative diseases such as 
Parkinson’s disease (Van Bulck et al. 2019) (Das et al. 2020). 
 
Another aspect involving AD progression is neuronal cells death. The lack of an active 
division in neurons result in the incapacity of this cell type to be replaced upon cell 
death. As a result, neuronal network and connectivity can be jeopardized resulting in 
 
cognitive and memory deficit in AD patients. The development of a cell therapy aimed 
to replace the dead cells by using stem cells transplants could reverse the psychiatric 
symptomatology by restoring the neuronal architecture (Derakhshankhah et al. 2020).  
 
There are a number of potential targets that could modify the progression of AD and 
alter the usual outcome. However, the complexity and multifactorial nature of the 
disease could prevent the success of a single-target drug as universal AD therapy. 
Thus, the development of a multi-targeted strategy could result in an effective way to 
treat AD. 
  
1.4.5 Novel compounds 
The compounds tested in this work were kindly provided by Prof. Jinyi Xu (China 
Pharmaceutical University – Nanjing). The novel drugs structure is derived from the 
(±)-7,8-Dihydroxy-3-methylisochroman-4-one [(±)-XJP] compound, which was 
initially isolated from the Musa sapientum L (Wang et al. 2015). This compound was 
then added with an N- N-benzyl pyridinium moiety, reported to have AChE inhibitory 
properties, with different –R group. Compound with 4-F as R group, 1-(4-
fluorobenzyl), named XJP-1 (Fig.1 A) was shown to have the lowest AChE half-
maximal inhibitory concentration (IC50) of 8.93nM (Wang et al. 2015).  Docking 
studies also showed that XJP-1 is able to bind both sites of AChE enzyme, peripheral 
anionic site (PAS), and the catalytic active site (CAS), which confers XJP-1 a higher 
specificity for AChE enzyme, over butyrylcholinesterase (BuChE). This is an 
important details, since many of the side effects reported by commercial AChE 
inhibitor Tacrine, were reported to be a consequence of aberrant BuChE inhibition 
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(Sharma 2019). Following the design and synthesis of compounds XJP-1, novel AChE 
inhibitors were from XJP-1 structure, named SAD-2, SAD-6 and FAD (Fig.1 B-D). 
In addition to this, given the relevance and central role of GSK3-β enzyme in multiple 
pathways during AD pathogenesis, Prof. Xu research group designed and synthesized 
a novel dual AChE/GSK3-β inhibitor, named 16g (Fig.1 E) (data not yet published). 
The latter is a Tacrine-pyrimidone hybrid derivate, with an IC50 for AChE and GSK3-
β of 50nM, and 89nM respectively (data not yet published).  
All compounds have a in silico predicted BBB penetration, and are water soluble (data 
not published yet). 
 
No. Compd. Structures 
A XJP-1 
 
Name: (E)-4-((5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl)-1-(3-fluorobenzyl)pyridin-1-ium bromide 
B SAD-2 
 











Figure 1. Novel compounds structure 
AChE inhibitors and dual AChE/GSK3-β inhibitors structure and IUPAC name. A) XJP-1. B) 
SAD-2. C) SAD-6. D) FAD. E) 16g.  
 
1.5 Thesis aim and hypothesis  
AD is a neurodegenerative disease affecting millions of people around the world. The 
multiple pathways involved, and the unclear triggering mechanism, are currently 
limiting the discovery of any effective therapy able to modify the progression of this 
disease.  
Our hypothesis proposes a series of novel AChE inhibitors, and AChE/GSK3-β dual 
target inhibitor as potential AD therapy.  
We believe that a higher specificity, of the newly synthesized compounds, for the 
AChE over BuChE could enhance their efficacy in slowing the AD progression, or 
improve the cognitive functions for a longer period. We also speculated that inhibition 
of both AChE and GSK3-β enzymes would results in disease modifying effects, 
particularly preventing GSK3-β induced Tau hyprophosphorylation.  
In order to test our hypothesis, we firstly aimed to generate an AD model, using 
Drosophila melanogaster, with measurable AD-like defects. Secondly, we tested the 
available compounds on the fruit fly models, highlighting the limitation of the current 
compounds, which resulted in an improvement of the initial AChE inhibitor into a dual 
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AChE/GSK-3β inhibitor. Lastly, we tested the best compound developed within this 
project on a novel neuron-like model we generated to study Tau aberrant 
phosphorylation. 
  
2 Materials and methods 
2.1 Reagents  
AChE inhibitors Donepezil, Galantamine and Rivastigmine were purchased from 
Sigma-Aldrich Ltd. NMDAR antagonist Memantine was purchased from Sigma-
Aldrich Ltd. Drug candidates XJP-1, SAD-2, SAD-6, FAD, and 16g were gifted by 
Prof. Jinyi Xu (CPU – Nanjing). 
All drug were dissolved in ddH2O to make a stock with a final concentration of 1mM.  
 
2.2 Drosophila melanogaster strains and cross schemes 
List of Drosophila melanogaster strains are outlined in Table 1.  
Flies were kept at 25°C in 25mL plastic vials containing 5ml of standard fly food, or 
standard fly food containing the appropriate drug concentration. To obtain Aβarc flies, 
20 elav-Gal4 (Ref. M19 – kindly provided by Dr. Georgiou – University of 
Nottingham) virgin females were crossed with 5 UAS-APPE693G males (Ref. 33774 
– Bloomington Indiana Drosophila stock centre). To obtain Tau flies, 20 elav-Gal4 
virgin females were crossed with 5 UAS-Tau males (Ref.51363 - Bloomington Indiana 
Drosophila stock centre). To obtain TBA flies, 20 elav-Gal4 virgin females were 
crossed with 5 UAS – MAPT -  BACE1 – APP males (Ref. 33799 - Bloomington 
Indiana Drosophila stock centre). To obtain Aβ42 flies 20 elav-Gal4 virgin females 
were crossed with 5 UAS – Abeta1-42 males (Ref. 32037 - Bloomington Indiana 
 
Drosophila stock centre). The female progeny of each cross scheme was used for all 
the assays (except REP experiments).  Elav-Gal4 flies were used as a wild type (WT) 
control.  
In REP experiments, gmr-Gal4 flies were used to drive the expression of the transgene 
of interest in the Drosophila compound eye. Thus, to obtain Aβarc flies, 20 gmr-Gal4 
(Ref. M572 – kindly provided by Dr. Georgiou – University of Nottingham) virgin 
females were crossed with 5 UAS-APPE693G males (Ref. 33774 – Bloomington 
Indiana Drosophila stock centre). To obtain Tau flies, 20 gmr-Gal4 virgin females 
were crossed with 5 UAS-Tau males (Ref.51363 - Bloomington Indiana Drosophila 
stock centre). To obtain TBA flies, 20 gmr-Gal4 virgin females were crossed with 5 
UAS – MAPT -  BACE1 – APP males (Ref. 33799 - Bloomington Indiana Drosophila 
stock centre). To obtain Aβ42 flies 20 gmr-Gal4 virgin females were crossed with 5 
UAS – Abeta1-42 males (Ref. 32037 - Bloomington Indiana Drosophila stock centre). 
Table 1. Drosophila Melanogaster strains 





2.3 Drosophila food preparation  
Flies were fed using the standard fly food recipe containing (quantity for 1 litre): 
70.62ml of golden syrup, 15.87g of yeast, 9.12g of soya flour, 67g of cornmeal, 5.25g 
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of agar, and 711.25ml of water. To add the drug of interest into the food, an aliquot of 
the drug stock solution was dissolved in a volume of water evenly to a 1/5th of the 
total food volume and mixed on the magnetic stirrer for 2 minutes. Subsequently, when 
the food was cooling down (Temperature < 80°C), the diluted drug was added and 
mixed it homogenously. Food containing drugs was then stored at +4̊ C up to three 
weeks.  
 
2.4 Rough Eye Phenotype Experiment 
The cross scheme for REP experiments is described in section 2.2. Flies were crossed 
on standard fly food or on drug containing food. Female progeny was analysed within 
24 hours after eclosion and after 10 days of respective drug treatment. Prior the eye 
imaging, the flies are anesthetized on CO2 pads, and the transferred under the Leica 
MZ10 F microscope (Leica) for the live imaging. All the eye pictures were taken using 
a 4x magnification and an exposure time of 15ms. All images have been acquired using 
the Qcapture software (Qimaging).   
 
2.5 Lifespan Assay 
Newly emerged flies aged 0-24 hours were collected and placed into fresh food vials 
containing 5mL of fly food. Each vial contained a group of maximum 20 flies. At least 
100 flies per genotype were analysed. Food vials containing the flies were kept 
horizontally in order to avoid the deaths due to sticky food. Food replacement occurred 
3 times a week, number of dead flies was counted at that time. Lifespan assay was 
performed until all flies into a vial have died. Flies that flew away, died in the food or 
trapped in the cotton lid were not taken in to account.  
 
 
2.6 Climbing assay 
Wild type and transgenic Drosophila locomotive functions were measured by 
performing the climbing assay. Flies aged 0-24 hours were collected and placed into 
fresh food vials containing the appropriate treatment. Each food vial contained up to 
10 flies. Food was replaced 3 times a week, for a total of three weeks, and at this time 
the climbing performances were recorded as follow: flies were moved into an empty 
50ml falcon tube, flies were then gently tapped down a and allowed to climb. The 
number of flies above the three cut off lines (40ml, 30ml and 20ml) were counted after 
20 seconds. The results are then calculated using the following formula:  
 
Climbing Index = (percentage of total flies above the 40ml line) x 1   
   + (percentage of total flies between the 30ml and 40ml lines) x 0.75  
   + (percentage of total flies between the 20ml and 30ml lines) x 0.50.   
 
2.7 Drosophila melanogaster brain immunostaining 
Adult flies were firstly anesthetized with CO2, and subsequently euthanized in pure 
ethanol. Brains were dissected in Phosphate Buffered Saline (PBS) and then fixed in 
4% paraformaldehyde (PFA) for 20 minutes at room temperature (RT). Tissues were 
then washed three times in 1% PBS-Tween 20 (PBS-T) for 2 minutes, and 
subsequently placed in 5% Normal Goat Serum (NGS) in PBS-T for 2 hours at room 
temperature. After removing the 5% NGS-T the rabbit anti-Aβ42 primary antibody 
(#ab2539, Abcam plc.) was added at a final concentration of 1:200 in 5% NGS-T and 
left to incubate overnight at +4̊ C. The primary antibody was then washed with 1% 
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PBS-T for three times and subsequently the goat – anti rabbit secondary antibody was 
added to a final 1:250 concentration. The sample was allowed to incubate for 1 hour 
at room temperature. Goat anti-Rabbit 488 Alexa Fluor secondary antibody (#A-
11034; ThermoFisher Scientific) was then washed with 1% PBS-T for three times. 
Brain samples were then mounted for confocal imaging exploiting a “bridge” structure 
to avoid any sample damage cause by the coverslip. Two 0.1mm thin coverslips were 
attached to the glass slide at approximately 5mm distance to each other. Subsequently, 
20µl of mounting media (90% PBS and 10% glycerol) were added in the gap between 
the two coverslips. Samples were then placed into the mounting media, and an 
additional cover slip to bridge the gap between the two “pylons” coverslips. Samples 
were analysed by confocal microscopy within 24 hours from mounting.  
 
2.8 Confocal microscopy  
All brain images were acquire using the Zeiss880 Confocal Microscope. Laser power 
was set up at 2.5%, gain at 520. Digital offset was set at 200. Acquiring speed at 1.03s 
averaging 2 times per slice. Cells images were acquired using Zeiss880 Confocal 
Microscope (Zeiss). Laser power was set at 4%, gain 650. Digital offset at 350. 
Acquisition speed was set at 1.3m averaging 2 times per image. Z-stack images at 
distance of 5µm were acquired. 
 
2.9 Images analysis  
A macro was created in ImageJ (Fiji) to identify and measure Amyloid spots in the 
images scanned at with the confocal microscope. The processing and analysis was 
carried out following the steps: raw, 16 bit confocal images were imported into ImageJ; 
 
maximum projection,focus stack flattening,was applied and we created a copy of this 
image; the copy will be used for object identification and creation of the mask; a 
Gaussian blur filter was applied to the image to smooth the noise pixels; a threshold 
of 14850-61890 was used to separate the plaques signals from the rest of the image 
and from the background; the lower value of thresholding 14850 was determined by 
using negative control and non-stained areas of the brain; top value we set just below 
the maximum to avoid occasionally appearing large clumps of overexposed areas;  a 
mask was created based on the thresholded areas; particle analysis was carried out on 
the mask while fluorescent intensity measurements were done by redirecting the 
measure function to the original image; the particle analysis was carried out to generate 
size, intensity and shape measurements of the plaques. 
 
2.10  Western Blot  
For Drosophila Melanogaster samples, a total of 50 fly heads for each sample were 
dissected and frozen overnight at -80˚C. Samples were then homogenized on ice in 
RIPA buffer ( 0.22% Beta glycerophosphate, 10% Tergitol-NP40, 0.18% Sodium 
orthovanadate, 5% Sodium deoxycholate, 0.38% EGTA, 1% SDS, 6.1% Tris, 0.29% 
EDTA, 8.8% Sodium chloride, 1.12% Sodium pyrophosphate decahydrate) (#89901, 
ThermoFisher Scientific) containing 1X protease inhibitor cocktails (AEBSF, 
aprotinin, bestatin, E-64, leupeptin, and pepstatin A) (#201119, Abcam plc.). 
Subsequently, samples were centrifuged at 16000G for 15 minutes at 4˚C. The 
supernatant was then transferred into a fresh clean vial. Protein were quantified as 
described by Bradford (Au - Ernst et al. 2010).  Following quantification, equal 
amount of samples were mixed with 4X Nu-Page LDS Sample Buffer (Invitrogen) and 
loaded into Nu-Page 4-12% Bis-Tris Gel (Invitrogen). Protein were then transferred 
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on 0.2µM nitrocellulose membrane (Bio-Rad) via Trans-Blot Turbo (Bio-Rad) semi-
dry apparatus. The membrane was then incubated for 1 hour at room temperature in 
5% skim milk in TBS-T, and subsequently incubated overnight at 4˚C with the 
appropriate primary antibody at a final concentration of 1:2500, either loading control 
rabbit polyclonal anti-Actin antibody (#ab1801, Abcam plc.), or rabbit monoclonal 
anti-amyoid1-42 antibody (#ab180956, Abcam plc). Each membrane was then washed 
three time with TBS-T and then incubated for 1 hour at room temperature with HRP 
conjugated secondary antibody at a final concentration of 1:5000. Membrane were 
then imaged using LAS-4000 (Fujifilm), and imaged analysed using ImageJ software 
(Fiji).  
 
2.11 Quantification of AChE-induced Aβ42 aggregation 
Measurements of AChE-induced amyloid aggregation were taken following the 
protocol reported by (Jiang et al. 2019). Briefly, hexafluoroisopropanol (HFIP)-treated 
E22G Aβ peptides (# SP-Ab-11_0.1, JPT – Innovative Peptide Solution) were 
dissolved in DMSO to reach a final 200µM stock. The dissolved peptides were 
subsequently centrifuged at 13500g for 10 minutes, the supernatant was then 
transferred into a fresh vial used for the following experiments. To evaluate the 
aggregation rate in presence of AChE inhibitors, 2µL of the compound of interest (at 
the appropriate concentration) were added into each vial, followed by 2µL of 200µM 
Aβ peptides stock, 20µL AChE enzyme (#C3389-500UN, Sigma-Aldrich ltd) (2U/mL, 
in 1X PBS at pH 8.0), and 76µL of 1X PBS pH 8.0.  The reaction was then incubated 
at RT for 24 hours. Subsequently, 100µL of 5µM Thioflavin T (ThT) were added into 
each vial. After one-hour incubation at RT, fluorescence emission was recorded at 
490nm with an excitation wavelength of 450nm using a Tecan Spark microplate 
 
reader. Results were then processed as done by Jiang and colleagues (Jiang et al. 2019) 
using the subsequent formula: (Fi – Fb)/(Fo  - Fb) x 100. Where Fi correspond to amyloid 
aggregation in presence of peptides, AChE, AChE inhibitors and ThT; Fo represents 
the amyloid aggregation in presence of peptides, AChE and ThT; Fb corresponds to 
blank control containing ThT only. 
 
2.12  SH-SY5Y culture and neuronal differentiation 
SH-SY5Y cells were cultured on different types of media, described in Table N.2, and 
differentiated as described by Shipley with some modifications (Shipley 2016). 
Briefly, SH-SY5Y were plated with Basic Growth media and allowed to reach 70% 
confluency. Subsequently, media was changed to Differentiation media #1 and replace 
every 48 hours for the following 7 days. Cells were then split 1:1 and moved into fresh 
flasks/dishes and Differentiation Media # 2 was added. Differentiation Media #2 was 
then replaced every 48 hours for the following 4 days. Subsequently, media was 
changed with Differentiation media #3 and replaced every 48 hours for the following 
7 days. After this period SH-SY5Y derived neurons were used for the subsequent 
assays and analysis.  
 
Table 2. Cell culture media for SH-SY5Y neuronal differentiation 
Breakdown of different cell culture media used for SH-SY5Y differentiation protocol 
 
 
Basic Growth Media Differentiation media #1 Differentiation media #2 Differentiation media #3
EMEM EMEM EMEM Neurobasal
15% hiFBS 2.5% hiFBS 1% FBS 20mM KCl
1x Pen/Strep 1x Pen/Strep 1x Pen/Strep 1x Pen/Strep
2mM Glutamine 2mM Glutamine 2mM Glutamine 2mM Glutamax




2.13  Glyceraldehyde (GA) induced Tau hyperphosphorylation 
In order to induce Tau hyperphosphorylation, differentiated SH-SY5Y were treated 
with either 0.7mM or 1mM GA for 24 hours as previously described (Koriyama et al. 
2015). After 24 hours treatment with GA, cells were used for downstream analysis.  
 
2.14  AChE activity assay (Ellman’s method) 
Acetylcholinesterase activity was assessed using acetylcholinesterase assay kit 
(#ab138871, Abcam plc.) following the manufacturer instruction. A total of 105 per 
well were seeded into a clear 96-well plate. After appropriate differentiation and 
treatment, cell culture media was removed, and 100µl of lysis buffer were added into 
each well and left to incubate for 15 minutes at room temperature (RT). Subsequently, 
50µl of acetylthiocholine reaction mixture (1X assay buffer, 1X DTNB stock solution, 
1X acetylthiocholine stock solution) were added to each well and samples were left to 
incubate for 30 minutes at room temperature. Samples were then analysed using a 96-
well microplate reader at OD= 410 ± 5 nm. In order to avoid false positive given by 
butyrylcholinesterase activity, the specific AChE inhibitor Donepezil hydrochloride 
was used as control.  
 
2.15  Cell viability assay 
A total of 105 per well were seeded into a 96-well plate. After SH-SY5Y 
differentiation, cells were treated with either 0.7mM or 1mM GA respectively. Along 
with GA treatment, appropriate concentration of the compounds to be tested was 
added. After 24 hours, 25l of 5mg/ml Methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) (#M2128-100MG, Sigma-Aldrich) were added into each well without 
 
removing cell culture media and incubated at 37˚C with 5% CO2 for 2 hours. 
Subsequently, 100l of lysing buffer (50% SDS solution, 25% DMF, 25% 
Demineralised water) were added. After an overnight incubation (20hrs) at 37C, the 
optical densities at 490nm were measured using 96-well plate reader. The 
medium/MTT/lysing buffer incubated under the same conditions was used as the 
control. 
  
2.16  pTAU quantification 
Phosphorylation levels of Tau protein on Serine 199 and S396 were quantified using 
Enzyme Linked Immunosorbent Assay methodology. Following the manufacturer 
recommended protocol, ELISA kits KHB7041, KHB7031, and KHB0041 
(ThermoFisher Scientific) were used to quantify phosphorylated Tau S199, 
phosphorylated S396, and total Tau respectively. Phosphorylation percentage was 
obtained, for the analysed residues, by normalization against total Tau. 
 
2.17  Immunostaining cell culture 
SH-SY5Y cells and differentiated SH-SY5Y cells were fixed in 4% PFA for 10 
minutes at minutes at room temperature. Each sample was then washed three times 
with 0.1% PBS-T for 2 minutes. Following fixation, cells were incubated at room 
temperature for 2 hours in 5% NGS-T blocking solution, and incubated overnight at 
+4̊ C with the mouse monoclonal anti-tubulin III primary antibody (#ab179513, 
Abcam plc.) at a final concentration of 1:1000. Primary antibody was then removed, 
and each sample was washed three times with 0.1% PBS-T. Rabbit anti-mouse 
secondary antibody Alexa Fluor 488 (#ab150113, Abcam plc.) was then added at a 
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final 1:2000 concentration, and left to incubate at RT for 1 hour. Secondary antibody 
was then removed, and each sample was washed three times with 0.1% PBS-T. 
Samples were then mounted on to glass slide, using FluoroGel Mounting media 
(Genetex). Samples were then imaged by confocal microscopy within 24 hours. 
 
2.18 Morphological analysis of SH-SY5Y derived neurons 
Analysis of confocal images was performed using ImageJ plug-in NeuronJ. Three of 
more random areas were analysed. A threshold mask was applied to visualize the axon 
only and not the cell body. Subsequently measurement of the axon length were taken, 
and distance between coordinates measured with NeuronJ.  
 
2.19 Data analysis  
All statistical analysis is performed using GraphPad Prism 9 software. Data obtained 
was firstly tested for normality using the Shapiro-Wilk test. Kaplan-Meier test was 
used to compare different survival curves. Kruskal-Wallis test followed by Dunn’s 
post-hoc was used to compare the differences between three or more groups in non-
normally distributed data. ANOVA test was used to compare the differences between 
three or more groups of normally distributed samples. ANOVA repeated measures 
analysis of variance followed by Dunn’s post-hoc test was used to analyse the 
differences between three or more groups in the climbing assay. Each experiment has 
been performed in triplicate and all results are presented as mean ± standard error of 
the mean, or mean ± standard deviation. 
Results with a P-value <0.05 were considered as significant. *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001. n indicates the number of independent experiment 





3 Drosophila model development and characterisation 
3.1 Introduction 
AD and related dementias are characterised by numerous different symptoms, 
triggered by an array of multiple pathways. To investigate either the basic biological 
mechanisms underlying the disease progression, or potential treatments, the 
development, and choice, of a reliable model is always necessary. Since the first-case 
report by Alois Alzheimer in 1907 a number of different AD models have been 
developed (Tue et al. 2020). Generating an AD model has mainly relied on the usage 
of genetic tools to knockout selected genes, or to deliver the expression of mutant 
proteins, involved in either the amyloidogenic cascade, or Tau hyperphosphorylation 
(Duyckaerts et al. 2008). The AD models so far developed include mice, 2D cells, 3D 
organoids, Zebrafish, and Drosophila Melanogaster (Papadimitriou et al. 2018; 
Newman et al. 2014; Coleman et al. 2017; Koriyama et al. 2015; Sivanantharajah et 
al. 2019). In particular, the fruit fly has been recognised as important tool to study both 
AD mechanisms and potential therapies (Tue et al. 2020). The development of 
Drosophila AD models has mainly relied on the overexpression of the human genes 
involved in either amyloidogenic pathway, or the human Tau protein (both mutant and 
wild type) by exploiting the UAS/Gal4 system to overcome the lack of functional AD-




Table 3. UAS-Gal4 system representation.  
The parental generation harbour either the elav-Gal4 gene, or the UAS-GFP gene, preventing 
the expression of the GFP protein. After crossing the parental lines, the progeny is able to 
express the GFP gene as it harbour both element of the UAS-Gal4 system.  
 
 
Among the various transgenic AD flies, the most widely used have been strains 
expressing Aβ peptides, the BACE1/APP proteins, and human Tau protein (either wild 
type or mutant) (Hwang et al. 2019; Cornelison et al. 2019; Miyazaki et al. 2019; 
Zhong et al. 2019; Higham et al. 2019; Pham et al. 2018; Zhang, Li, et al. 2016; Sandin 
et al. 2016; Chakraborty et al. 2011). In addition to this, reports of familial AD forms, 
where patients harbour a mutant gene, for instance the APP Arctic mutation, have 
further extended the AD models developed exploiting Drosophila melanogaster.  
In addition to this, induced REP by expression of the AD toxic protein in the 
developing eye has served as quick model to study neuronal defects. The REP has  
been used to study amyloid and tau derived neurotoxicity by quantifying, or simply 
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visualizing, the eye size and ommatidia architecture, and to identify potential AD 
treatment by screening for those therapies able to revert the induced REP (Zhong et al. 
2019; Zhang, Li, et al. 2016).  
Drosophila AD models have been employed in drug screening projects, involving 
plant derived products as well (Ali et al. 2019; Hwang et al. 2019; Miyazaki et al. 
2019; Zhong et al. 2019; Pham et al. 2018; Zhang, Li, et al. 2016; Sandin et al. 2016; 
Mhatre et al. 2014).  
 
3.1.1 Experimental aim 
Despite a large number of Drosophila Melanogaster AD models have been developed, 
often different results are reported on the recorded symptomatology. (Ogunsuyi et al. 
2020; Liu et al. ; Kizhakke P et al. 2019).  
In the work presented below, we evaluated different Drosophila AD models 
expressing Aβ42-peptides, Tau/APP/BACE1 proteins, Tau 2N4R, and mutant APP 
E693G (Arctic mutation) protein. For each genotype, we characterised different 
symptomatology induced by the transgene expression in the CNS. We also exploited 
the REP model to investigate whether AD derived neurodegeneration can be studied 
in the Drosophila developing eye, and use it for further drug screening purposes.  
 
3.1.2  Experimental procedures 
This chapter describes the data collected using 4 experimental procedures as follows: 
1- Characterisation of transgene expression effects on Drosophila Melanogaster 
lifespan. 
2- Investigation on locomotive functions in different AD genotypes. 
3- Screening for different transgene expression in developing a Rough Eye Phenotype 
 
4- Characterization of Tau and Aβarc flies CNS at multiple time points. 
 
3.2 Results 
3.2.1 Expression of human Tau and mutant APP protein lead to reduced 
lifespan and locomotive defects 
To investigate the effects of pan-neuronal expression of AD-related transgenes on 
Drosophila melanogaster survival time, a lifespan assay was performed (Fig.2). 
Among the transgenic Drosophila expressing the human AD proteins, flies carrying 
the mutant E693G APP protein (hereafter referred to as Aβarc flies), and transgenic 
Tau-2N4R Drosophila (hereafter referred to as Tau flies), recorded an almost halved 
survival time when compared to the wild type control (Fig.2 A, B). Further to this, 
transgenic flies expressing Tau 2N4R, BACE1 enzyme, and APP protein (hereafter 
referred to as TBA flies) showed a significant drop in life expectancy, with similar 
results recorded for transgenic Drosophila expressing the amyloid-β1-42 peptide 
(hereafter referred to as Aβ42 flies) (Fig.2 A, B). To address whether the expression of 
transgenic AD protein would affect the fruit fly locomotive functions as well, we 
performed a climbing assay. Locomotive activity measurements were recorded for 21 
days, and showed a significant time-dependant drop in climbing scores for Aβarc 
Drosophila, with transgenic flies showing a significant reduction at each time point 
analysed (Fig.3 A). On the other hand, Tau flies showed fluctuant climbing scores, 
with significant locomotive defects being recorded for the first 14 days of analysis, 
with the exception of day 7, but not during the last week of analysis (Fig. 3B). Other 
than that, both TBA and Aβ42  flies did not show any progressive locomotive defects, 
with climbing scores being significantly lower than the wild type at three time points 











Figure 2. Transgenic AD Drosophila lifespan 
A) Kaplan-Meier survival trajectories of different Drosophila AD genotypes. B) Mean 
survival time of transgenic AD flies. Kuskar-Wallis test followed by Dunn’s post-hoc was used 
to compare the differences between different groups. Data are expressed as mean ± SEM, n = 
3 (number of independent experiments, each experiment, with a minimum of 10 animals per 







Figure 3. Evaluation of different Drosophila AD genotypes locomotive functions  
Data shows the climbing performance trends over a 21 day period. Data generated from 
the climbing index was processed as a percentage of the total. In order to compare vials 
with a different number of flies, repeated measures analysis of variance was used to 
compare climbing scores between treated and untreated groups. A) Climbing assay of 
Aβarc flies. B) Climbing assay of Tau flies. C) Climbing assay of TBA flies. D) Climbing 
assay of Aβ42 flies.  
Data is presented in the figure as the mean ± SD.  n = 3 (number of independent 
experiments, each experiment, with a minimum of 10 animals per treatment).  P<0.05 was 




3.2.2 Ommatidia neurodegeneration in Aβarc and Tau transgenic flies 
In order to investigate the effects of AD-related proteins at neuronal levels, the gmr-
Gal4 was exploited to drive the expression within the Drosophila developing eye. This 
methodology exploits the architecture of compound eye of the fruit fly, composed by 
hundreds of ommatidia, each one presenting 8 photoreceptor neurons. Eyes of the flies 
expressing AD-related proteins were analysed within 24 hours post eclosion. Among 
transgenic Drosophila, only Tau flies showed a clear REP, whilst Aβarc, TBA, and 
Aβ42 did not show any visible difference compared to the wild type control (Fig.4 A).  
To understand whether a REP would be detectable at more advanced stage of 
Drosophila adulthood, we analysed again transgenic AD flies after 7 days post 
eclosion, Once again, among all genotypes analysed only Tau flies showed a visible 
REP, while the other AD flies showed an eye morphology identical to the wild type 
(Fig.4 B). In addition to this, we hypothesized that the expression of the AD-related 
transgene might have been affected by the flies growing temperature of 25˚C. Thus, in 
an attempt to increase the transgene expression, transgenic AD flies were grown at 
29˚C and analysed within 24 hours post-eclosion. Tau and Aβarc flies showed a visible 
REP compared to the wild type, whilst no differences were recorded for TBA and Aβ42 
flies (Fig.4 C). The minimal effects recorded in TBA and Aβ42 flies in the REP 
analysis, and previous carried out analysis suggests that these transgene are not 
suitable to induce AD in Drosophila melanogaster, for this reasons they were not 























Figure 4.  REP development by expressing different AD transgene  
A) Eye images of different AD genotypes at day one post eclosion, flies were grown at 25˚C. 
B) Eye images of different AD genotypes at day 7 post eclosion, flies were grown at 25˚C. C) 




3.2.3 Characterisation of transgenic Aβarc flies and Tau flies brain  
AD patients’ brains are characterised by the presence of amyloid plaques and 
neurofibrillary tangles, which are composed of β-peptides aggregates and 
hyperphosphorylated Tau protein respectively. To study whether these features are 
present in the fruit fly model we generated, we exploited confocal microscopy to 
visualize the Aβarc and Tau Drosophila CNS after 10 and 20 days post-eclosion (Fig.5 
A). Quantification of the amyloid aggregates (hereafter referred to as amyloid spots) 
in Aβarc flies showed a significant increase in 10 days old flies (Fig.5 B) when 
compared to the wild type control. Moreover, the same trend was recorded after the 
analysis of 20 day old Aβarc flies’ brains (Fig.5 C), despite no significant difference 
was recorded between 10 and 20 days Aβarc Drosophila. 
In order to analyse the Tau Drosophila’ brains, we stained them using a monoclonal 
antibody against phosphorylated S396 of human Tau protein, a specific residue 
analysed to estimate Tau protein phosphorylation levels, which is also considered as 
early stage marker of AD (Mondragón-Rodríguez et al. 2014).  Signal intensity 
analysis of the Tau flies’ brains showed a significant increase in the Tau group when 
compared to the wild type control at 10 and 20 days post-eclosion (Fig.5 D, E).  These 
findings suggests that the AD symptoms recorded in both Aβarc flies and Tau flies are 
directly reputable to the accumulation of amyloid spots and NFTs within the AD 


















Figure 5. Effects of Tau and Aβarc-peptides expression on CNS 
A) Confocal representative images of Drosophila melanogaster expressing either Tau, or 
Aβarc-peptides (arrow indicates amyloid spots), at 10 and 20 days post eclosion. Scale bar 
100µm B) Whole brain quantification of amyloid spots at 10 days post eclosion in Aβarc flies. 
Mann-Whitney test was used to compare the differences between two different groups, P<0.05 
was considered as significant. C) Whole brain quantification of amyloid spots at 20 days post 
eclosion in Aβarc flies. Mann-Whitney test was used to compare the differences between two 
different groups, P<0.05 was considered as significant. D) Whole brain quantification of 
immunostaining intensity at 10 days post eclosion in Tau flies. Mann-Whitney test was used 
to compare the differences between two different groups, P<0.05 was considered as 
significant. E) Whole brain quantification of immunostaining intensity at 20 days post eclosion 
in Tau flies. Mann-Whitney test was used to compare the differences between two different 
groups, P<0.05 was considered as significant.  Data is presented as mean ± SEM. n = 3 , with 







Drosophila melanogaster is powerful and efficient in vivo model of a number of 
human diseases, such as Parkinson’s, cancer and AD (Feany et al. 2000; Rudrapatna 
et al. 2012; Tue et al. 2020). Because of the defined lifespan, behaviour and easily 
accessible CNS, Drosophila models of neurodegenerative diseases can serve as quick 
in vivo tool for initial screening of compounds libraries. Previously reported 
Drosophila models have relied on the expression of either Aβ42, or Tau, in order to 
study the pathophysiological effects of these two crucial hallmarks in AD progression 
(Cornelison et al. 2019; Nepovimova et al. 2014).  
Our results indicate that the expression of the Aβ peptides harbouring the Arctic 
mutation, as well as the expression of human Tau isoform 2N4R, lead to the 
development of Drosophila models characterised by a symptomatology similar to that 
described in human patients. Both Tau and Aβarc flies recorded the most severe 
reduction in the survival time when compared to the wild type control. In addition to 
this, Tau and Aβarc flies have showed significant reduction of their locomotive 
functions, whilst TBA and Aβ42 did not. Moreover, expression of Tau (at both 25˚C 
and 29˚C) and Aβarc (at 29˚C only) in the ommatidia resulted in a REP. In contrast, 
TBA and Aβ42 flies did not develop any REP, further suggesting that the expression of 
these transgene was not suitable to develop a reliable AD model.  
To further characterise the selected genotypes as AD model, we investigated the 
protein deposition features present in the fly CNS at multiple time points. We 
successfully detected deposition of amyloid plaques, as early as 10 days post-eclosion 
in Aβarc flies, with the same trend being recorded at 20 days post-eclosion. Tau flies, 
 
showed a significant increase in phosphorylation levels on S396, at both time points 
when compared to the wild type control.  
To summarize, we have screened different human AD transgene expression in 
Drosophila melanogaster, and evaluated multiple parameters related to the human 
symptomatology. The expression of mutant Aβ peptides and Tau 2N4R has led to the 
development of fruit fly AD models, which symptoms and neuroanatomical features 
have been quantified. In addition to this, we provided a novel time recorded analysis 
for amyloid deposition and Tau hyperphosphorylation. 
 The characterised parameters of Aβarc and Tau Drosophila can be used to evaluate the 




4 XJP-1 treatment ameliorates amyloid-induced symptomatology 
in Aβarc flies 
4.1 Introduction 
The brain of AD patients is characterised by the presence of amyloid plaques, which 
are recognised as one of the key hallmarks for this disorder. They are formed of 
amyloid β-peptides, secreted by neurons, which form insoluble toxic aggregates that 
lead to local neuroinflammatory and neurodegenerative responses (Gouras et al. 2005; 
Meyer-Luehmann et al. 2008). The amyloidogenic pathway can generate amyloid β-
peptides of various lengths, ranging from 17-42aa. Sequential cleavages of the amyloid 
precursor protein performed by β- and γ-secretase, is required to generate neurotoxic 
Aβ peptide, which is primarily 40 or 42aa in length (Yan et al. 1994; Pike et al. 1993).  
To date, the mechanism activating the amyloidogenic pathway is still unknown, with 
the exception of genetic mutations causing familial AD (Trambauer et al. 2020).   
In particular mutation in APP gene, such as the Swedish (Lys595Asn), London 
(Val717Ile), and Arctic (Glu693Gly), are known to cause early-onset AD (Shin et al. 
2010; Talarico et al. 2010; Nilsberth et al. 2001).  The APP gene harbouring the Arctic 
mutation, is known to cause sever cognitive and locomotive defects, along with 
accumulation of amyloid plaques since early stages of AD (Basun et al. 2008; Norlin 
et al. 2012). In addition, Aβ peptides bearing the Arctic mutation are known to have a 
faster aggregation rate, compared to the wild type form, resulting in a rapid formation 
of protofibrils, which are known to be severely synaptotoxic (Johansson et al. 2006; 
O'Nuallain et al. 2010).  
Despite not a clear link between cholinergic network and amyloid cascade, several 
reports highlight the involvement of the cholinergic system in AD pathogenesis and 
progression (Hampel et al. 2018).  
 
According to the cholinergic hypothesis, a drop in the level of cholinergic markers, 
acetylcholine and acetyl-transferase, is the starting point of AD pathogenesis in the 
brain. Furthermore, depletion of acetylcholine is linked with an aberrant vasomotor 
control of the BBB, leading to a defective clearance of the amyloid peptides (Hunter 
et al. 2012).  
Thus, targeting acetylcholinesterase for AD therapy is still a promising route, due to 
strong evidence linking AChE enzyme to amyloid aggregation (Nepovimova et al. 
2014; Inestrosa et al. 1996; Jiang et al. 2019).  It has been suggested that AChE 
facilitates amyloid aggregation by acting as a nucleation point, in particular the PAS 
is strongly linked with this function (Lushchekina et al. 2017). Thus, the development 
of new AChE inhibitors, able to both increase the level of acetylcholine, therefore 
improve cognitive symptomatology, and also reduce the available AChE surface for 
amyloid interaction, and subsequent aggregation, remain an open challenge.  
The FDA has also approved an NMDAR antagonist, named Memantine, as an AD 
therapy. Several reports have highlighted the involvement of the glutamatergic system 
in AD disease progression (Tayeb et al. 2012). Memantine is as well administrated in 
combination with Donepezil in patients with severe cases of AD, therapy named 
Namzaric, despite some disagreeing reports on the further beneficial effects of this 
combined therapy (Parsons et al. 2013).  
.  
4.1.1 Experimental aim 
Following the characterization of the Drosophila melanogaster AD model expressing 
the mutant amyloid peptide harbouring the Arctic mutation, we have evaluated the 
efficacy on the induced symptomatology of the novel AChE inhibitor XJP-1 after 
reports of efficacy in vitro (Wang et al. 2015; Wang et al. 2018).  
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We have exploited the same Aβarc Drosophila model to evaluate the efficacy of all the 
currently approved FDA therapy on this particular model, in order to further compare 
the results obtained from our drug candidate to the drugs used at various stages of AD. 
 
4.1.2 Experimental procedures 
This chapter describes the data collected using 4 experimental procedures as follows: 
1- Efficacy evaluation of all therapies studied in improving Aβarc flies survival 
time. 
2- Effects of therapies studied on amyloid-induced locomotive defects. 
3- Quantification of CNS amyloid spots after treatments at multiple time points.  
4- Evaluation of amyloid peptides aggregation rate in presence of AChE enzyme 
alone, and with AChE inhibitors.  
 
4.2 Results 
4.2.1 XJP-1 treatment improves life expectancy in Aβarc flies 
In order to find the appropriate dosage to treat flies, we attempted to replicate previous 
published result in which Donepezil was administrated at 30µM dosage to treat AD 
Drosophila model (Zhang, Wang, et al. 2016).  
Aβarc flies treated with 30µM Donepezil, did not show any significant increase of the 
survival time, with the same results being replicated at 0.2mM and 0.4mM (Fig.S1 A, 
B). We then decided to further increase the Donepezil concentration to 0.5mM, which 
resulted in a significant improvement of Aβarc flies survival time (Fig.S1 A, B). 
To understand whether this would be replicated by XJP-1, Aβarc flies were treated with 
0.5mM and 0.4mM concentration of the novel compound. However, XJP-1 treatment 
at these concentrations resulted in a toxic effect, with a drop of the survival time 
 
compared to control group (Fig.S1 C, D). Thus, We decided to reduce XJP-1 
concentration to 40µM, which resulted in a significant increase in the mean survival 
time of Aβarc flies, with around 40% of the entire population surviving after day 40, 
despite Aβ peptides expression (Fig.S1 C, D).  
Similar results were also recorded with other FDA approved AD drugs, including the 
AChE inhibitors Donepezil (0.5mM final concentration), Rivastigmine (0.1mM final 
concentration), and the NMDAR antagonist Memantine (0.5mM final concentration), 
with XJP-1 having better results than Galantamine (0.5mM final concentration) on 
Aβarc survival time (Fig.6 A, B), despite XJP-1 was administrated at 40µM.  
Since the FDA currently approves a combined therapy of Memantine and Donepezil, 
we investigated whether XJP-1 and Memantine treatment would further enhance the 
results obtained by XJP-1 alone. Both FDA approved combined therapy, and XJP-1 
plus Memantine, showed a significant improvement of the Aβarc Drosophila lifespan 
(Fig.6 A, B). However, no significant difference was recorded when the combined 















Figure 6. Aβarc flies lifespan under different treatment 
A) Kaplan-Meier survival trajectories of AβArc flies under different drug treatments. B) Mean 
survival time of AβArc flies on different treatments. Kuskar-Wallis test followed by Dunn’s 
post-hoc was used to compare the differences between different groups. Data are expressed as 
mean ± SEM, n = 3 with a minimum of 100 animal per experiment. P<0.05 was considered as 
significant. * P<0.05; **P<0.01; *** P<0.001; ****P<0.0001. 
  
 
4.2.2  XJP-1 treatment improves locomotive functions in Aβarc flies 
The climbing assay is a behavioural test, based on negative geotaxis against gravity, 
which is used to assess locomotive functions in Drosophila (Au - Nichols et al. 2012).  
Aβarc flies recorded a time-dependent worsening of climbing ability, thereby faithfully 
recapitulating symptoms observed in human patients (Fig.7 A).  
Inhibition of AChE enzyme by XJP-1 resulted in a significant amelioration of the 
locomotive symptomatology in Aβarc flies (Fig.7 B). In addition to this, among the 
FDA approved therapies only Donepezil treatment showed results comparable to XJP-
1 (Fig.7 C).  On the other hand,  Rivastigmine, Galantamine and Memantine treatment 
did not results in a constant beneficial effects on locomotive functions, as seen in flies 
treated with XJP-1 and Donepezil (Fig.7 D-F). Following the same trend, flies treated 
with combined therapies did not show any significant improvement when compared 
to untreated Aβarc Drosophila, and worst results when compared to XJP-1, Memantine, 






Figure 7. Treated Aβarc flies climbing assay 
Aβarc flies climbing assay under different treatments. Data shows the climbing performance 
trends over a 21 day period. Data generated from the climbing index was processed as a 
percentage of the total. In order to compare vials with a different number of flies, repeated 
measures analysis of variance was used to compare climbing scores between treated and 
untreated groups. A) Climbing assay of Aβarc flies untreated. B) Climbing assay of Aβarc flies 
 
XJP-1 treated. C) Climbing assay of Aβarc flies Donepezil treated. D) Climbing assay of Aβarc 
flies Rivastigmine treated. E) Climbing assay of Aβarc flies Galantamine treated. F) Climbing 
assay of Aβarc flies Memantine treated. G) Climbing assay of Aβarc flies XJP-1 and Memantine 
treated. H) Climbing assay of Aβarc flies Donepezil and Memantine treated.  Data presented in 
the figure as the mean ± SD.  n = 3 (number of independent experiments, each experiment, 
with a minimum of 10 animals per treatment).  P<0.05 was considered as significant. * P<0.05; 
**P<0.01; *** P<0.001; ****P<0.0001.  
 
4.2.3 XJP-1 reduces the number of amyloid plaques in the brain  
The deposition, accumulation, and aggregation of amyloid peptides in the CNS is a 
crucial point in the development of Alzheimer’s symptomatology. Using confocal 
microscopy, we found that Aβarc fly brains to possess large and extensively distributed 
amyloid spots at 10 days post-eclosion (Fig.8 A). To understand whether treatment 
with XJP-1, or commercially available therapies, would result in any change in 
amyloid pathology in the CNS, we imaged Aβarc fly brains following 10 days of 
treatment (Fig.8 A). Subsequent quantification showed a significant reduction in 
amyloid spots count in flies treated with either XJP-1, or XJP-1 and Memantine 
combined. None of the commercially approved therapies had comparable results to the 
new AChE inhibitor (Fig.8 B). To further investigate whether there was a remarkable 
difference in amyloid spots count in those brain areas rich in cholinergic neurons, we 
exploited the Fly Brain Observatory software to determine areas of the brain that are 
rich in cholinergic neurons. We found that mushroom bodies (Fig. 9A), fan-shaped 
bodies (Fig.9 B), Medulla (Fig. 9 C), and Optic Lobes (Fig. 9 D), were rich in 
cholinergic neurons compared to other areas such as Antennal Lobes (Fig.9 E) and 
subesophageal ganglion (Fig.9 F) (Xu et al. 2020). Analysis of Mushroom body and 
Fan-shaped body areas recorded a significant reduction of amyloid spots in flies treated 
with both XJP-1 monotherapy, and XJP-1 and Memantine combined therapy (Fig.8 
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C). Conversely, none of the treatments tested had a beneficial impact on the Medulla 
and Optic lobe amyloid spots count (Fig.8 D). 
 To assess whether AD progression alters these amyloid spots count results, we also 
analysed the Aβarc flies brains at 20 days post-eclosion (Fig.10 A). The whole brain 
analysis showed a significant reduction of the amyloid spots count, similar to that 
observed at 10 days, in flies treated with XJP-1, Donepezil, and Memantine, whilst 
Galantamine and Rivastigmine failed to show any significant effect (Fig.10 B). The 
same reduction trends were recorded in the Mushroom bodies and Fan-Shaped bodies 
(Fig.10 C). Although none of the treatments tested reduced the amyloid spot counts in 
the Medulla and Optical Lobes areas after 10 days (Fig.10 D), analysis of samples 
treated for 20 days showed a significant decrease in the amyloid spot levels for all 
treatment tested, with exception of Galantamine and Rivastimgine (Fig.10 D). The 
combined therapies investigated however, did not show any further beneficial effects 





















Figure 8. Amelioration of amyloid spots in Aβarc flies CNS after 10 days of treatment.  
A) Representative confocal images of WT (top left panel) or Aβarc brains; arrows show 
amyloid spots; scale bar: 100µm. B) Whole brain quantification of amyloid spots. ANOVA 
test followed by Bonferroni's post hoc was used to compare the differences between three or 
more groups, P<0.05 was considered as significant.  C) Mushroom body and fan-shaped body 
quantification of amyloid spots. ANOVA test followed by Bonferroni's post hoc was used to 
compare the differences between three or more groups, P<0.05 was considered as significant.  
D) Medulla and Optic lobe quantification of amyloid spots. ANOVA test followed by 
Bonferroni's post hoc was used to compare the differences between three or more groups, 
P<0.05 was considered as significant.  Data are presented as mean ± SEM. n = 3, with a 
68 
 










Figure 9. Representative images of cholinergic neurons network in Drosophila 
Melanogaster brain obtained from the Virtual Fly Observatory  
A) Cholinergic neurons within the mushrooms bodies. B) Cholinergic neurons within the fan-
shaped bodies. C) Cholinergic neurons within the medulla. D) Cholinergic neurons within the 
optic lobes. E) Cholinergic neurons within the antennal lobes. F) Cholinergic neurons within 
the subesophageal ganglion. 
The different colours observed in the image do not highlight any difference among neurons. 






Figure 10.  Amelioration of amyloid spots in Aβarc flies CNS after 20 days of treatment  
A) Representative confocal images of WT (top left panel – bright mark is a gastroesophageal 
residue carried during dissection) or Aβarc brains; arrows show amyloid spots; scale bar: 
100µM. Bright central spot is a gastroesophageal residue carried during dissection B) Whole 
brain quantification of amyloid spots. ANOVA test followed by Bonferroni's post hoc was 
used to compare the differences between three or more groups, P<0.05 was considered as 
significant. C) Mushroom body and fan-shaped body quantification of amyloid spots. 
ANOVA test followed by Bonferroni's post hoc was used to compare the differences between 
three or more groups, P<0.05 was considered as significant.  D) Medulla and Optic lobe 
quantification of amyloid spots. ANOVA test followed by Bonferroni's post hoc was used to 
compare the differences between three or more groups, P<0.05 was considered as significant.  
Data are presented as mean ± SEM. n = 3, with a minimum of 1 animal per experiment 




4.2.4 XJP-1 reduces amyloid aggregation via AChE inhibition  
To confirm that the observed reduction in amyloid spot aggregation was not a result 
of a reduced quantity of amyloid peptides within the Aβarc fly brains, we quantified 
amyloid peptide expression following 10 and 20 days of treatment. At both time points, 
and for all drug treatments, amyloid peptide expression was statistically similar to 
untreated brains (Fig.S3 A-D). This result was expected since the expression of the 
transgene is determined by the UAS/Gal4 system and is not targeted by any of the 
drugs studied. We hypothesized that the AChE enzyme was functioning as a nucleation 
point for amyloid peptide aggregation, as previously reported (Inestrosa et al. 1996; 
Rees et al. 2003; Lushchekina et al. 2017).  
We used an in vitro assay to evaluate Aβarc peptides aggregation rate in presence of 
AChE enzyme and inhibitors.  
Aβ peptides carrying the Arctic mutation were co-incubated with AChE enzyme in 
presence, or not, of all the AChE inhibitors tested as therapy, or as combined therapy. 
We found a significant drop in all treatments studied, with the greatest reductions 
observed for XJP-1 and Donepezil, both recording an almost 80% decrease in 
aggregation rate (Fig.11). Once again, the combined therapies did not result in any 




Figure 11. Reduction of AChE-induced Aβ-peptide aggregation rates in the presence of 
AChE Inhibitors 
ANOVA test followed by Bonferroni's post hoc was used to compare the differences between 





Over the past 10 years, the fruit fly has emerged as a powerful in vivo model for 
neurodegenerative diseases, including AD (Tue et al. 2020; Ali et al. 2019; Hwang et 
al. 2019; Cornelison et al. 2019; Miyazaki et al. 2019; Higham et al. 2019; 
Sivanantharajah et al. 2019; Pham et al. 2018; Zhang, Li, et al. 2016). Transgenic 
Drosophila AD models have been employed as a model organism for a number of drug 
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testing studies involving different targets such as AChE, GSK-3β, lysozyme, Tau 
protein and dopaminergic receptors. (Miyazaki et al. 2019; Sandin et al. 2016; Pham 
et al. 2018; Zhong et al. 2019; Hwang et al. 2019; Zhang, Li, et al. 2016; Ali et al. 
2019). In the work described in this chapter, we demonstrated the capacity of a new 
compound, XJP-1, to reduce amyloid-β aggregation, and consequent amelioration of 
the behavioural phenotype in the Aβarc transgenic Drosophila AD model.   
 
Further to this, we have tested all commercially available therapies, including 
combined therapy Donepezil and Memantine, showing that XJP-1 treatment results in 
a better, or comparable, improvement of AD symptomatology at a much lower 
concentration than the FDA approved therapies.  
XJP-1 treatment resulted in an overall improvement of the amyloid induced defects, 
with an increase of mean survival time of about 13 days, and an amelioration of the 
locomotive functions throughout the entire assay time. The benefits observed in the 
amyloid-derived symptomatology are the results of the reduction of amyloid plaques 
within the Drosophila brain, because of the potent drop in amyloid aggregation rate 
induced by AChE enzyme in presence of XJP-1. Flies treated with Donepezil obtained 
similar results, except for the 10 days analysis of amyloid spots count where this 
treatment did not result in any significant difference. Other than that, our results also 
show a discrepancy from already published work, in which Donepezil was claimed to 
effectively improve transgenic AD Drosophila at a concentration as low as 30µM 




XJP-1 and Memantine combined treatment did not result in a further significant 
improvement when compared to XJP-1 treatment alone, as well as Donepezil and 
Memantine therapy, which did not result in any further improvement when compared 
to the monotherapy. It has to be clarified that combined therapy is usually only given 
to patients when they enter an advanced stage of the disease, when Memantine is added 
to patients already on Donepezil therapy (Tayeb et al. 2012; Parsons et al. 2013).  
In this study, all drugs were administrated continuously from 24 hours upon eclosion, 
including combined therapies, giving a possible explanation on why Donepezil with 
Memantine, and XJP-1 with Memantine, did not show any further beneficial effect, 
when compared to single therapy on this AD model. This highlighted limitation may 
explain as well, the poor efficacy of Galantamine and Rivastigmine compared to 
Donepezil, as they are currently prescribed to Alzheimer’s patients with mild to 
moderate stages of AD, whilst Donepezil is given to AD patients at all stages of the 
disease, from mild to severe (Haake et al. 2020).  
 
Our study has shown a clear involvement of AChE inhibition on amyloid aggregation 
resulting in a symptomatology amelioration. The effect of XJP-1 on Aβarc transgenic 
flies were partially replicated only by Donepezil at a concentration 10 times higher 
than our drug candidate, with XJP-1 having better results in reducing the amyloid spots 
count after 10 days of treatment. Other than that, the other FDA approved AChE 
inhibitors, Galantamine and Rivastigmine, reduced the amyloid aggregation rate of 
about 50%, whilst XJP-1 and Donepezil reduced it of about 80%, giving a potential 
explanation for the limited beneficial effects observed in Aβarc flies treated with 
Galantamine and Rivastigmine. 
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Docking studies carried out on XJP-1 showed a dual-binding property for both the 
peripheral anionic site (PAS) and catalytic active site (CAS) of AChE enzyme (Wang 
et al. 2015), which may further explain the low dosage needed to slow down the 
amyloid aggregation, since the PAS of AChE has been linked to increase Aβ-peptides 
aggregation rate (Inestrosa et al. 1996). Despite not being tested in this study, XJP-1 
was predicted to have anti-inflammatory and anti-oxidant properties (Wang et al. 
2018; Wang et al. 2015), which may have as well played a role in ameliorating the AD 
symptomatology in Aβarc flies.  
  
 
5 AChE inhibition by XJP-1 treatment does not result in reduction 
of Tau phosphorylation in Drosophila melanogaster AD model 
5.1 Introduction  
AD and related dementias are characterised by the presence of neurofibrillary tangles, 
as a results of the abnormal phosphorylation of Tau protein (Bloom 2014). The latter 
is a MAP encoded by the MAPT gene, which contains a number of different residues 
potentially target of post-translational modifications (Götz et al. 2019). Tau protein 
serves as microtubule stabilizer, by promoting tubulin polymerization, which in 
neurons plays crucial role in axon morphology and axonal transport (Kadavath et al. 
2015). In a number of different neurodegenerative diseases, Tau protein undergoes a 
number of post-translational modifications, in particular phosphorylation, leading to a 
loss of affinity to the microtubules, which results in a loss of microtubule architecture 
and axon morphology in neurons (Götz et al. 2019).   
To study this neuroanatomical feature, Drosophila Melanogaster was successfully 
exploited to develop several AD model of Tau hyperphosphorylation, by expressing 
human Tau isoform 2N4R in a pan-neuronal manner (Cornelison et al. 2019; Higham 
et al. 2019; Sivanantharajah et al. 2019; Sun et al. 2015).  
Moreover AD Drosophila models have been used to investigate drug efficacy and to 
perform drug screening to target Tau toxicity and hyperphosphorylation, which results 
can be easily translated to higher species due to the highly conserved pathways 





5.1.1 Experimental aim 
As described in the previous chapter, we have successfully proved XJP-1 efficacy in 
ameliorating AD symptomatology in Aβarc flies. In addition to this, we have 
demonstrated that XJP-1 treatment results in a reduction of amyloid spots in the fruit 
fly brain.  
Other than that, we successfully proved that AChE inhibition resulted in a slower Aβ 
peptides aggregation rate, giving a possible explanation for the reduction of amyloid 
spots within the Aβarc flies.   
Because of these findings, we decided to further investigating the effects of XJP-1 
treatment on another important AD hallmark, Tau hyperphosphorylation. 
The latter plays a crucial role in exacerbating AD cognitive symptomatology, and it is 
responsible of several other dementias known as tauopathies. In addition to this, AChE 
inhibition was reported to inhibit GSK3-β driven Tau hyperphosphorylation (Noh et 
al. 2009; Yoshiyama et al. 2010).  
Thus, we decided to investigate the effects of XJP-1 treatment, and FDA approved 
therapies, by exploiting the Tau Drosophila model we have developed as described in 
Chapter 3. 
 
5.1.2 Experimental procedures 
This chapter describes the data collected using 4 experimental procedures as follows: 
1- Efficacy evaluation of all therapies studies in improving Tau flies survival 
time. 
2- Effects of therapies studied on hyperphosphorylated Tau-induced locomotive 
defects. 
 
3- Quantification of phosphorylated S396 immunostaining signal at multiple time 
points after treatment.  
4- Investigation on the ability of all therapies studied in preventing REP derived 




5.2 Results  
5.2.1 XJP-1 treatment improves Tau flies lifespan, but does not result in 
improved locomotive functions 
Expression of human 2N4R isoform of Tau protein resulted in a significant drop in 
Drosophila survival time as previously described (Fig.2 A, B). To investigate the 
effects of the new AChE inhibitor XJP-1, Tau flies were fed with food containing a 
final 40µM concentration of the new compound. In order to assess the effects of the 
FDA therapies on this Drosophila model, separated groups of Tau flies were fed with 
the commercially available AD therapies.  
Flies fed with food containing a final 40µM concentration of XJP-1 recorded a 
significant increase in survival time when compared to the untreated group (Fig.12 A, 
B). A similar trend was recorded for Tau flies treated with 0.5mM Donepezil, and 
0.5mM Galantamine. On the other hand, Rivastigmine and Memantine treatment, 
administrated at 0.1mM and 0.5mM respectively, did not results in a significant 
increase of Tau flies lifespan. Other than that, combined therapies Donepezil plus 
Memantine, and XJP-1 plus Memantine, recorded a significant increment in Tau flies 
survival time, despite not recording a significant difference when compared to AChE 
inhibitors therapy alone (Fig.12 A, B).  
 
To assess whether XJP-1 treatment would results in an improvement of Tau flies 
climbing performances, a climbing assay on Tau expressing flies under different 
treatments was performed (Fig.13).  
Following an opposite trend from the result obtained on the lifespan assay, XJP-1 
treatment did not result in any significant improvement of the locomotive functions at 
any of the time points analysed (Fig.13 B). Donepezil, the most potent currently FDA 
 
approved therapy for AD treatment, improved Tau flies climbing scores at only one 
time point analysed, day 12, and failed to produce further significant improvement of 
the locomotive functions (Fig.13 C). On the same trend, Memantine, Galantamine, and 
Rivastigmine treatment did not record any significant difference when compared to 
the untreated Tau flies (Fig.13 D-F).   
Among the combined therapy tested, only XJP-1 plus Memantine, had a limited 
beneficial effect on Tau flies climbing scores, with a significant improvement being 
recoded at day 9 and 12 of analysis, whilst Donepezil plus Memantine did not score 
any significant difference from the untreated group (Fig.13 G, H) 
 
Figure 12. Tau flies lifespan under different treatment 
A) Kaplan-Meier survival trajectories of Tau flies under different drug treatments. B) Mean 
survival time of Tau flies on different treatments. Kuskar-Wallis test followed by Dunn’s post-
hoc was used to compare the differences between different groups. Data are expressed as mean 
± SEM, n = 3 with a minimum of 100 animals per experiment. P<0.05 was considered as 





Figure 13. Treated Tau flies climbing assay 
Tau flies climbing assay under different treatments. Data shows the climbing performance 
trends over a 21 day period. Data generated from the climbing index was processed as a 
percentage of the total. In order to compare vials with a different number of flies, repeated 
measures analysis of variance was used to compare climbing scores between treated and 
untreated groups. A) Climbing assay of Tau flies untreated. B) Climbing assay of Tau flies 
XJP-1 treated. C) Climbing assay of Tau flies Donepezil treated. D) Climbing assay of Tau 
flies Memantine treated. E) Climbing assay of Tau flies Galantamine treated. F) Climbing 
 
assay of Tau flies Rivastigmine treated. G) Climbing assay of Tau flies XJP-1 and Memantine 
treated. H) Climbing assay of Tau  flies Donepezil and Memantine treated.  Data are presented 
in the figure as the mean ± SD.  n = 3 (number of independent experiments, each experiment, 
with a minimum of 10 animals per treatment).  P<0.05 was considered as significant. * P<0.05; 
**P<0.01; *** P<0.001; ****P<0.0001.  
 
 
5.2.2 Tau hyperphosphorylation in Tau Drosophila cannot be prevented, 
or reduced, by XJP-1 treatment 
NTFs are a major consequence of Tau hyperphosphorylation, resulting in 
neurotoxicity and neuronal cells death. In order to estimate the phosphorylation levels 
of Tau protein within the Drosophila CNS, confocal microscopy was exploited to 
visualize phosphorylated Tau residue S396, which is considered to be a marker of the 
early stage of Tau hyperphosphorylation events (Foidl et al. 2018; Mondragón-
Rodríguez et al. 2014).  
We analysed Tau flies brain after 10 days of treatment (Fig.14 A) and recorded a 
significant increase in Tau phosphorylation at S396 when compared to the wild type 
control (Fig.14 B). Moreover, none of the treatment studied resulted in a significant 
reduction of the Tau phosphorylation when compared to the untreated group (Fig.14 
B).  
To investigate whether a continuous treatment for a longer period would result in any 
change in Tau phosphorylation levels, Tau flies were allowed to grow for 20 days on 
food containing the drugs under assessment. Confocal analysis, after 20 days, of Tau 
flies CNS (Fig.15 A) confirmed the same trend observed previously, with none of the 




















Figure 14. CNS analysis of Tau hyperphosphorylation after 10 days of treatment 
A) Representative confocal images of WT (top left panel) or Tau brains; scale bar: 100µM. B) 
Whole brain quantification of Tau (phosphor S396) immunostaining signal. ANOVA test 
followed by Bonferroni's post hoc was used to compare the differences between three or more 
groups, P<0.05 was considered as significant. Data are presented as mean ± SEM. n = 3, with 



















Figure 15. CNS analysis of Tau hyperphosphorylation after 20 days of treatment 
A) Representative confocal images of WT (top left panel) or Tau brains; scale bar: 100µM. B) 
Whole brain quantification of Tau (phosphor S396) immunostaining signal. ANOVA test 
followed by Bonferroni's post hoc was used to compare the differences between three or more 
groups, P<0.05 was considered as significant. Data are presented as mean ± SEM. n = 3, with 





5.2.3 XJP-1 treatment does not rescue REP induced by human Tau 
expression and hyperphosphorylation  
After all therapies under investigation recorded negative results on CNS analysis for 
Tau hyperphosphorylation, we decided to assess whether a partial neuroprotection 
from neurodegeneration resulting after Tau  aberrant phosphorylation could be 
achieved. To do so, we have exploited the REP induced by human Tau expression in 
the Drosophila eye. As each ommatidia is connected to 8 photoreceptor neurons, small 
defects in the complex architecture can be easily visualised.  
Tau expression in the Drosophila eye results in a jeopardized structure when compared 
to the wild type (Fig.16).  Among the drug we have assessed, only Donepezil at 0.5mM 
concentration completely rescued the Tau-induced phenotype. XJP-1 treatment, as 
well as the other FDA therapies, failed to produce any visible improvement in the 
ommatidia architecture (Fig.16).  
Surprisingly, none of the combined therapies tested rescued the REP, a results in 













Figure 16. Treated REP images  
REP images of flies under different treatment, scale bar 1mm. Visible ommatidia architecture 






Tau abnormal phosphorylation levels, and subsequent formation of NFTs, are one of 
the major challenges to be tackled in order to develop an AD therapy with disease-
modifying properties.  
The Drosophila model we have generated, well recapitulated the human 
symptomatology, with a shortened lifespan, locomotive defects and neurodegeneration 
(Xia et al. 2017; Shinosaki et al. 2000). In addition to this, Tau derived pathology has 
been recently highlighted as potential key-player in AD symptoms exacerbation 
(Busche et al. 2019).   
Treatment with novel AChE inhibitor resulted in limited beneficial effects, with 
significant improvements in the symptomatology recorded only in the lifespan assay. 
In contrast, XJP-1 failed to ameliorate the locomotive symptomatology, and to reduce 
Tau hyperphosphorylation in AD flies.  Further assessment on neuroprotection, 
through REP imaging, did not show any visible improvement in the ommatidia 
architecture. This is in contrast with the available literature, which claims that AChE 
inhibition results in an amelioration of climbing function, along with reduction of Tau 
phosphoprylation on similar Tau Drosophila model (Zhang, Wang, et al. 2016; Zhang, 
Li, et al. 2016). We hypothesize that activation of relevant ACh receptor can 
eventually play a role in preventing Tau  aberrant phosphorylation, but this cannot be 
controlled using by XJP-1 administration. The inhibition of AChE enzyme results in 
an increased level of ACh only, without specific activation of a post-synaptic receptor, 
suggesting a possible explanation for the poor results obtained. 
The investigation of efficacy of the FDA approved therapies on this particular model 
showed negative results as well, with the exception of Galantamine, Donepezil, and 
combined therapies studied, which therapy resulted in an increased survival time. 
 
Despite reports of Donepezil treatment being able to inhibit GSK3-β enzyme, and 
reduction of Tau phosphorylation levels, we were not able to replicate these results on 
this particular model (Noh et al. 2009). In fact, Donepezil treatment rescued the REP, 
and increased the survival time of Tau flies only, whilst no significant reduction of 
Tau phosphorylation levels was recorded after both 10 and 20 days of treatment.  
Moreover, 30µM Donepezil treatment was reported to improved locomotive functions 
of  human Tau expressing Drosophila, in a time period up to 40 days (Zhang, Li, et al. 
2016). In this study, we have showed that 0.5mM Donepezil does not result in any 
improvement of the climbing scores.  
None of the AChE inhibitors tested resulted in a drop in Tau phosphorylation, 
suggesting that a more specific target within Tau phosphorylation pathway is needed 




6 Development and characterization of neuron-like model of AD 
and screening of novel AChE and dual AChE/GSK3-β inhibitors 
6.1 Introduction  
The identification of novel therapeutic targets able to modify the natural course, and 
progression, of AD is a crucial step to revert the outcome of the disease.  
In this context, NFTs resulting from Tau hyperphosphorylation have been highlighted 
as potential target with disease-modifying properties (Tapia-Rojas et al. 2019; Mi et 
al. 2006). Multiple factors are involved in the triggering of Tau hyperphosphorylation, 
such as amyloid plaques, glucose metabolism impairment, and RAGE-pathway 
activation (Gasparotto et al. 2018; Lauretti et al. 2017; Bloom 2014). Despite through 
different pathways, all factors involved in altering Tau phosphorylation levels lead to 
the activation of specific kinases enzyme, or inhibition of phosphatases enzymes (Götz 
et al. 2019).  
In particular, GSK3-β enzyme has been defined to be responsible of Tau 
phosphorylation on several residues, disrupting the protein binding affinity to 
microtubules (Wagner et al. 1996). GSK3-β is responsible of phosphorylating Tau on 
residue S396, which abnormal phosphorylation is considered to be an early marker of 
subsequent hyperphosphorylation (Foidl et al. 2018). GSK3-β is the downstream 
kinase activated by multiple pathways linked to Tau hyperphosphorylation (Zhang et 
al. 2020; Foidl et al. 2018; Chu et al. 2017; Li, Liu, et al. 2012; Batkulwar et al. 2018). 
Thus, targeting GSK3-β could result in the inhibition of Tau phosphorylation induced 
by multiple pathways in AD and, therefore, blocking the disease progression.  
Further to innovative drug candidates, novel AD models are necessary. In fact, many 
AD models have intrinsic biases which makes it difficult to perform drug screenings. 
Drosophila melanogaster models, have been developed by overexpressing human 
 
genes, involved in AD pathogenesis, especially mutant genes reported in familial cases 
of AD, despite genetic AD accounts for only 1% of the total patients (Sivanantharajah 
et al. 2019; Tue et al. 2020; Nikolac Perkovic et al. 2019). Moreover, the fruit fly 
model does not allow to have an homogenous dosage among different flies, since the 
drug is administrated within the food. Mice AD models mainly rely as well on the 
expression of mutant proteins present in familial forms of the disease, in addition to 
having a complicated route for ethical approval of any experiment (Davis et al. 2004).   
Novel approaches exploiting AD patient derived iPSC have some limitations as well, 
mainly due to the heterogeneity of epigenetic modification, which differ from each 
donor, that can be maintained after reprogramming protocols (Drummond et al. 2017).  
Cell-line SH-SY5Y has been used as cell-culture model of AD, despite bearing the 
crucial limitation of being constantly dividing, a feature not present in human neurons 
(Himeno et al. 2011; Yan et al. 1994; Shang et al. 2019; Da Pozzo et al. 2014). 
However, several approaches have been proposed to further improve the SH-SY5Y 
cell model. Different neuronal differentiation protocols have been defined using 
mainly retinoic acid as differentiation factor, and deprivation of FBS to enter cells in 
G0 phase and, therefore, preventing cells division (Shipley 2016; Agholme et al. 2010; 
Constantinescu et al. 2007; Korecka et al. 2013; Presgraves et al. 2003). Moreover, a 
number of methods exploiting undifferentiated SH-SY5Y have achieved Tau 
hyperphosphorylation through different mechanisms, such as hypothermia, okadaic 
acid administration, and glyceraldehyde exposure (Zhang and Simpkins 2010; 
Bretteville et al. 2012; Koriyama et al. 2015). In particular, the usage of GA to induce 
Tau hyperphosphorylaiton is of peculiar interest, since GA treatment leads to increased 
levels of AGEs, which receptor, RAGE, activates an important and well-studied 
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pathway in  GSK3-β activation (Koriyama et al. 2015; Li, Liu, et al. 2012; Batkulwar 
et al. 2018).  
 
6.1.1 Experimental aim 
Our approach to target AChE enzyme with XJP-1 to treat AD has resulted in 
contradictive results, in which the novel inhibitor produced significant amelioration of 
the AD symptomatology induced by amyloid peptides overexpression, but failed on 
improving the AD symptomatology in Tau Drosophila model. To overcome this 
problem, Prof. Xu research group (CPU – Nanjing) has synthesized a novel dual 
AChE/GSK3-β inhibitor in order to reduce AChE-induced amyloid aggregation, and 
to prevent GSK3-β catalysed Tau phosphorylation. In addition to this, Prof. Xu 
provided several novel AChE inhibitors to be tested, which structure was derived from 
XJP-1, and have lower IC50.  
To better study this new molecules, we decided to develop a novel cell culture AD 
model by combining RA-induced differentiation of SH-SY5Y cell lines, along with 
GA treatment to induce Tau hyperphosphorylation (Koriyama et al. 2015; Shipley 
2016). 
 
6.1.2 Experimental procedures 
This chapter describes the data collected from 6 different experimental procedures: 
1. Differentiation of SH-SY5Y into neurons. 
2. Characterization of GA treatment, at different concertation, on SH-SY5Y derived 
neurons morphology. 
3. Characterization of GA treatment, at different concentration, on SH-SY5Y derived 
neurons Tau phosphorylation on residue S199 and S396. 
 
4. Characterization of GA treatment, at different concentration, on SH-SY5Y derived 
neurons cells viability.  
5. Characterization of novel AChE inhibitors, novel dual AChE/GSK3-β inhibitor, 
and control drugs Donepezil (AChE inhibitor) and Tideglusib (GSK3-β inhibitor) 
on novel AD model. 
6. Evaluation of AChE-induced amyloid aggregation rate in presence of novel AChE 





6.2.1 GA treatment induces abnormal Tau phosphorylation and axon 
degeneration in SH-SY5Y-differentiated neurons 
In order to develop a neuron-like model of AD bearing Tau hyperphosphorylation, 
differentiation of SH-SY5Y in neurons was firstly performed as described by Shipley 
(Shipley 2016). SH-SY5Y derived neurons were subsequently imaged by confocal 
microscopy (Fig.17 A) to compare morphological differences. Differentiated neurons 
exhibited a significant increment in neurite density and neurite length when compared 
to undifferentiated SH-SY5Y cells (Fig.17 B, C).  
After validating neuronal differentiation of SH-SY5Y cells, we investigated whether 
GA treatment for 24 hours would results in any AD defects in differentiated neurons, 
as described by Koriyama in undifferentiated SH-SY5Y cells (Koriyama et al. 2015). 
Confocal imaging, and subsequent axon length analysis, showed a significant 
reduction of neurite length in neurons treated with 0.7mM GA and 1mM GA when 
compared to untreated neurons (Fig.17 A, C). In addition to this, an assessment of Tau 
phosphorylation levels was performed on neurons treated with GA. Tau residue S199 
was found to be abnormally phosphorylated following administration of both 0.7mM 
GA and 1mM GA (Fig.17 D). The same trend was recorded on S396 residue, recording 
a significant increment of phosphorylation levels following 0.7mM GA and 1mM GA 
administration (Fig.17 E).  
Furthermore, we evaluated whether GA treatment, and resulting Tau 
hyperphosphorylation, would result in any change in neuronal cells viability. To assess 
neuronal viability, an MTT assay was performed 24 hours after GA administration, 
with both 0.7mM GA and 1mM GA treatment resulting in a significant drop in cells 



















Figure 17. Initial characterization of novel AD model 
A) Confocal images of SH-SY5Y cells, SH-SY5Y-derived neurons, and SH-SY5Y neuron 
treated with 0.7mM GA or 1mM GA. B) Neurite density quantification of SH-SY5Y cells and 
SH-SY5Y derived neurons. Mann-Whitney test was used to compare differences between 
different groups. C) Neurite length quantification of SH-SY5Y cells, SH-SY5Y derived 
neurons, and SH-SY5Y derived neurons following GA treatment at different concentration. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
differences between different groups. D) Quantification of phosphorylation ratio pTau/tTau 
on S199 of SH-SY5Y differentiated neurons following 0.7mM GA or 1mM treatment. 
ANOVA followed by Tukey’s post-hoc test was used to compare differences between different 
groups. E) Quantification of phosphorylation ratio pTau/tTau on S396 of SH-SY5Y 
differentiated neurons following 0.7mM GA or 1mM GA treatment. ANOVA followed by 
Tukey’s post-hoc test was used to compare differences between different groups. F) Cell 
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viability assay of SH-SY5Y differentiated neurons following GA treatment at different 
concentration. Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to 
compare differences between different groups. 
Data are presented as mean ± SEM. n = 3, with a minimum of 5 repetition per experiment 
analysed. * P<0.05; **P<0.01; *** P<0.001; ****P<0.0001.  
  
 
6.2.2 Novel compounds inhibit AChE enzyme activity in SH-SY5Y 
differentiated neurons 
Upon validation that GA treatment results in Tau abnormal phosphorylation in SH-
SY5Y derived neurons, we decided to investigate the inhibitory activity of the novel 
AChE inhibitors provided.  
In 0.7mM GA exposed neurons we recorded a significant inhibition of AChE activity 
by XJP-1 at a concentration up to 0.5µM, with the same trend being scored by all other 
AChE inhibitors investigated (Fig.18 A-E). However, Donepezil and FAD showed a 
significant inhibition at 50nM concentration as well in 0.7mM GA treated neurons 
(Fig.18 B, E).  
Investigation on dual AChE/GSK3-β inhibitor 16g showed a significant inhibition at 
5µM concentration only (Fig.18 F).   
Study on 1mM GA exposed neurons showed a drop in AChE activity following 
treatment with all inhibitors tested at a concentration up to 50nM with the exception 





















Figure 18. AChE inhibition by novel compounds at different concentration in 0.7mM GA 
exposed SH-SY5Y-derived neurons 
A) Inhibitory activity of compound XJP-1 in 0.7mM GA exposed neurons. B) Inhibitory 
activity of compound Donepezil in 0.7mM GA exposed neurons. C) Inhibitory activity of 
compound SAD-2 in 0.7mM GA exposed neurons. D) Inhibitory activity of compound SAD-
6 in 0.7mM GA exposed neurons. E) Inhibitory activity of compound FAD in 0.7mM GA 
exposed neurons. F) Inhibitory activity of compound 16g in 0.7mM GA exposed neurons. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
differences between different groups. Data are presented as mean ± SEM. n = 3, with a 
minimum of 5 repetition per experiment analysed. * P<0.05; **P<0.01; *** P<0.001; 

















Figure 19. AChE inhibition by novel compounds at different concentration in 1mM GA 
exposed SH-SY5Y-derived neurons 
A) Inhibitory activity of compound XJP-1 in 1mM GA exposed neurons. B) Inhibitory activity 
of compound Donepezil in 1mM GA exposed neurons. C) Inhibitory activity of compound 
SAD-2 in 1mM GA exposed neurons. D) Inhibitory activity of compound SAD-6 in 0.7mM 
GA exposed neurons. E) Inhibitory activity of compound FAD in 1mM GA exposed neurons. 
F) Inhibitory activity of compound 16g in 1mM GA exposed neurons. Ordinary one-way 
ANOVA followed by Tukey’s post-hoc test was used to compare differences between different 
groups. Data are presented as mean ± SEM. n = 3, with a minimum of 5 repetition per 
experiment analysed. * P<0.05; **P<0.01; *** P<0.001; ****P<0.0001.   
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6.2.3 AChE inhibition prevents GA-induced Tau phosphorylation on 
S396, but not on S199. 
After validating the inhibitory activity of the novel compounds on AChE enzyme 
(Fig.18, 19), we investigated whether GA-induced Tau hyperphosphorylation could be 
prevented by AChE inhibition exerted by novel compounds. Exposure of neuronal 
cells to 0.7mM GA dramatically increased Tau phosphorylation levels  on S199 
(Fig.17 D), whilst AChE inhibitor XJP-1, at 5µM and 0.5µM concentration, 
significantly reduced Tau hyperphosphorylation on S199 in neurons treated with 
0.7mM GA (Fig.20 A), with the same trend being scored by the control AChE inhibitor 
Donepezil (Fig.20 B). On the other hand, treatment with novel AChE inhibitors SAD-
2 did not reduce S199 phosphorylation in 0.7mM GA exposed SH-SY5Y 
differentiated neurons (Fig.20 C), whilst compounds SAD-6 and FAD recorded a 
significant reduction of S199 abnormal phosphorylation when administrated at 5µM 
concentration only (Fig.20 D, E). Moreover, in SH-SY5Y differentiated neurons 
treated with 1mM GA, none of the AChE inhibitors tested, including Donepezil, 
showed a significant reduction of Tau phosphorylation on S199 (Fig.21 A-E).  
To further assess the efficacy of the novel compounds in preventing Tau abnormal 
phosphorylation, another residue S396 was examined. In neurons treated with 0.7mM 
GA, all therapies under study showed a potent effect in reducing S396 
phosphorylation, at all concentration tested (Fig.22 A-E).  
Moreover, an overlapping trend was found in neurons treated with 1mM GA, with all 
the novel compounds inducing a significant reduction of phosphorylation levels on 
Tau S396, at a concentration as low as 10nM (except SAD-6) (Fig.23 A-E). Moreover, 




Figure 20. Tau S199 phosphorylation levels in 0.7mM GA exposed neurons after 
treatment with novel AChE inhibitors 
A) Quantification of phosphorylation ratio pTau/tTau on S199 of 0.7mM GA treated SH-
SY5Y differentiated neurons after XJP-1 treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S199 of 0.7mM GA treated SH-SY5Y differentiated neurons after Donepezil 
treatment. C) Quantification of phosphorylation ratio pTau/tTau on S199 of 0.7mM GA 
treated SH-SY5Y differentiated neurons after SAD-2 treatment. D) Quantification of 
phosphorylation ratio pTau/tTau on S199 of 0.7mM GA treated SH-SY5Y differentiated 
neurons after SAD-6 treatment. E) Quantification of phosphorylation ratio pTau/tTau on S199 
of 0.7mM GA treated SH-SY5Y differentiated neurons after FAD treatment. Kuskar-Wallis 
test followed by Dunn’s post-hoc was used to compare the differences between different 
groups. Data are expressed as mean ± SEM, n=3 with at least 5 repetition per 






Figure 21. Tau S199 phosphorylation levels in 1mM GA exposed neurons after treatment 
with novel AChE inhibitors 
A) Quantification of phosphorylation ratio pTau/tTau on S199 of 1mM GA treated SH-SY5Y 
differentiated neurons after XJP-1 treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S199 of 1mM GA treated SH-SY5Y differentiated neurons after Donepezil 
treatment. C) Quantification of phosphorylation ratio pTau/tTau on S199 of 1mM GA treated 
SH-SY5Y differentiated neurons after SAD-2 treatment. D) Quantification of phosphorylation 
ratio pTau/tTau on S199 of 1mM GA treated SH-SY5Y differentiated neurons after SAD-6 
treatment. E) Quantification of phosphorylation ratio pTau/tTau on S199 of 1mM GA treated 
SH-SY5Y differentiated neurons after FAD treatment. Kuskar-Wallis test followed by Dunn’s 
post-hoc was used to compare the differences between different groups. Data are expressed as 





Figure 22. Tau S396 phosphorylation levels in 0.7mM GA exposed neurons after 
treatment with novel AChE inhibitors 
A) Quantification of phosphorylation ratio pTau/tTau on S396 of 0.7mM GA treated SH-
SY5Y differentiated neurons after XJP-1 treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S396 of 0.7mM GA treated SH-SY5Y differentiated neurons after Donepezil 
treatment. C) Quantification of phosphorylation ratio pTau/tTau on S396 of 0.7mM GA 
treated SH-SY5Y differentiated neurons after SAD-2 treatment. D) Quantification of 
phosphorylation ratio pTau/tTau on S396 of 0.7mM GA treated SH-SY5Y differentiated 
neurons after SAD-6 treatment. E) Quantification of phosphorylation ratio pTau/tTau on S396 
of 0.7mM GA treated SH-SY5Y differentiated neurons after FAD treatment. Kuskar-Wallis 
test followed by Dunn’s post-hoc was used to compare the differences between different 
groups. Data are expressed as mean ± SEM, n=3 with at least 5 repetition per 





Figure 23. Tau S396 phosphorylation levels in 1mM GA exposed neurons after treatment 
with novel AChE inhibitors 
A) Quantification of phosphorylation ratio pTau/tTau on S396 of 1mM GA treated SH-SY5Y 
differentiated neurons after XJP-1 treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S396 of 1mM GA treated SH-SY5Y differentiated neurons after Donepezil 
treatment. C) Quantification of phosphorylation ratio pTau/tTau on S396 of 1mM GA treated 
SH-SY5Y differentiated neurons after SAD-2 treatment. D) Quantification of phosphorylation 
ratio pTau/tTau on S396 of 1mM GA treated SH-SY5Y differentiated neurons after SAD-6 
treatment. E) Quantification of phosphorylation ratio pTau/tTau on S396 of 1mM GA treated 
SH-SY5Y differentiated neurons after FAD treatment. F) Quantification of phosphorylation 
ratio pTau/tTau on S396 of 1mM GA treated SH-SY5Y differentiated neurons after 16g 
treatment. G) Quantification of phosphorylation ratio pTau/tTau on S396 of 1mM GA treated 
SH-SY5Y differentiated neurons after Tideglusib treatment. Kuskar-Wallis test followed by 
Dunn’s post-hoc was used to compare the differences between different groups. Data are 
 
expressed as mean ± SEM, n=3 with at least 5 repetition per experiment,*P<0.05; **P<0.01, 
***P<0.001, ****P<0.0001.  
 
6.2.4 Dual AChE/GSK3-β inhibitor 16g modulates Tau phosphorylation 
on S199 and S396 
To investigate the effects of treatment with dual GSK3-β/AChE inhibitor 16g, Tau 
phosphorylation on S199, in 0.7mM GA treated neurons was investigated. The novel 
compound showed a significant reduction of S199 phosphorylation levels, when 
compared to the untreated 0.7mM GA neurons, in a dose dependant manner up 50nM 
concentration (Fig.24 A), whilst commercial GSK3-β inhibitor Tideglusib reduced 
S199 phosphorylation at 5µM concentration only (Fig.24 B). However, the novel dual 
inhibitor, was not able to significantly reduce S199 phosphorylation in neurons 
exposed to 1mM GA (Fig.25 A, B), despite GSK3-β inhibitor Tideglusib successfully 
reduced S199 phosphorylation at 5µM and 0.5µM concentration (Fig.25 B).  
To further characterise the efficacy of compound 16g in reducing Tau 
hyperphosphorylation, residue S396 was examined. A significant drop in S396 
phosphorylation levels was recorded, up to 50nM concentration, in 0.7mM GA 
exposed neurons treated with compound 16g, with Tideglusib scoring similar results 
(Fig.26 A, B). Moreover, inhibition of both AChE and GSK3-β enzymes resulted in a 
significant reduction for all concentration tested of compound 16g in 1mM GA 
exposed neurons, with the same results being scored by the control drug Tideglusib 






Figure 24. Reduction of Tau S199 phosphorylation after 16g treatment in 0.7mM GA 
exposed neurons 
A) Quantification of phosphorylation ratio pTau/tTau on S199 of 0.7mM GA treated SH-
SY5Y differentiated neurons after 16g treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S199 of 0.7mM GA treated SH-SY5Y differentiated neurons after Tideglusib 
treatment. Kuskar-Wallis test followed by Dunn’s post-hoc was used to compare the 
differences between different groups. Data are expressed as mean ± SEM, n=3 with at least5 




Figure 25. Reduction of Tau S199 phosphorylation after 16g treatment in 1mM GA 
exposed neurons 
A) Quantification of phosphorylation ratio pTau/tTau on S199 of 1mM GA treated SH-SY5Y 
differentiated neurons after 16g treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S199 of 1mM GA treated SH-SY5Y differentiated neurons after Tideglusib 
treatment. Kuskar-Wallis test followed by Dunn’s post-hoc was used to compare the 
differences between different groups. Data are expressed as mean ± SEM, n=3 with at least 5 





Figure 26. Reduction of Tau S396 phosphorylation after 16g treatment in 0.7mM GA 
exposed neurons 
A) Quantification of phosphorylation ratio pTau/tTau on S396 of 0.7mM GA treated SH-
SY5Y differentiated neurons after 16g treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S396 of 0.7mM GA treated SH-SY5Y differentiated neurons after Tideglusib 
treatment. Kuskar-Wallis test followed by Dunn’s post-hoc was used to compare the 
differences between different groups. Data are expressed as mean ± SEM, n=3 with at least 5 




Figure 27. Reduction of Tau S396 phosphorylation after 16g treatment in 1mM GA 
exposed neurons 
A) Quantification of phosphorylation ratio pTau/tTau on S396 of 1mM GA treated SH-SY5Y 
differentiated neurons after 16g treatment. B) Quantification of phosphorylation ratio 
pTau/tTau on S396 of 1mM GA treated SH-SY5Y differentiated neurons after Tideglusib 
treatment. Kuskar-Wallis test followed by Dunn’s post-hoc was used to compare the 
differences between different groups. Data are expressed as mean ± SEM, n=3 with at least 5 




6.2.5 Efficacy of AChE inhibitors in preventing hyperphosphorylated 
Tau-induced neurodegeneration 
Microtubule architecture plays a fundamental role in cytoskeletal structure in neuronal 
cells, assuring a correct morphology and axonal transport. The presence of 
hyperphosphorylated forms of Tau protein lead to a jeopardized microtubule 
architecture, resulting in a disrupted axon morphology and neurodegeneration.  
Treatment with GA at 0.7mM and 1mM concentrations resulted in a dramatic 
increment of Tau phosphorylation levels, which led to morphology defects and neurite 
shortening (Fig.16 A, C).  
To assess whether any of the novel AChE inhibitors compounds was able to prevent 
the formation of morphological defects in GA treated neurons, we exploited confocal 
microscopy to image neurons treated with either 5µM or 0.5µM of the novel therapies. 
Treatment with AChE inhibitor XJP-1 resulted in increased axon length, with results 
being better than the positive control AChE inhibitor Donepezil, which failed to score 
any significant amelioration (Fig.28 A-C). On the other hand, AChE inhibitor SAD-2, 
SAD-6, and FAD were not able to prevent axon shortening at any of the concertation 
studied on 0.7mM GA treated neurons (Fig.28 D-F). Study on axon length in 1mM 
GA treated neurons (Fig.29  A),  confirmed that XJP-1 treatment significantly prevent 
neurite shortening, with better results than Donepezil, which was able to replicate XJP-
1 results only when administrated at 0.5µM concentration (Fig.29 B-C). Despite not 
scoring any significant improvement in neuronal morphology in 0.7mM GA treated 
neurons, AChE inhibitors SAD-2, SAD-6, and FAD, significantly prevented neurite 
























Figure 28. Morphological analysis of 0.7mM GA exposed neurons after different AChE 
inhibitors treatment 
A) Confocal images of SH-SY5Y-derived neurons under different treatment. B) Neurite length 
quantification of 0.7mM GA treated SH-SY5Y differentiated neurons after XJP-1 treatment. 
C) Neurite length quantification of 0.7mM GA treated SH-SY5Y differentiated neurons after 
Donepezil treatment. D) Neurite length quantification of 0.7mM GA treated SH-SY5Y 
differentiated neurons after SAD-2 treatment. E) Neurite length quantification of 0.7mM GA 
treated SH-SY5Y differentiated neurons after SAD-6 treatment. F) Neurite length 
quantification of 0.7mM GA treated SH-SY5Y differentiated neurons after FAD treatment. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
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differences between different groups. Data is presented as mean ± SEM, n=3 with at least 5 





















Figure 29. Morphological analysis of 1mM GA exposed neurons after different AChE 
inhibitors treatment 
A) Confocal images of SH-SY5Y-derived neurons under different treatment. B) Neurite length 
quantification of 1mM GA treated SH-SY5Y differentiated neurons after XJP-1 treatment. C) 
Neurite length quantification of 1 mM GA treated SH-SY5Y differentiated neurons after 
Donepezil treatment. D) Neurite length quantification of 1mM GA treated SH-SY5Y 
differentiated neurons after SAD-2 treatment. E) Neurite length quantification of 1mM GA 
 
treated SH-SY5Y differentiated neurons after SAD-6 treatment. F) Neurite length 
quantification of 1mM GA treated SH-SY5Y differentiated neurons after FAD treatment. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
differences between different groups. Data is presented as mean ± SEM, n=3 with at least 5 
repetition per experiment,*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.  
 
 
6.2.6 Treatment with compound 16g prevents Tau-induced 
neurodegeneration 
During AD progression, the formation of aggregated forms of hyperphosphorylated 
Tau leads to the disruption of neuronal morphology. As a consequence, neural 
architecture and connectivity is lost, therefore resulting in a loss of brain circuits and 
functions. Thus, prevention the neurite degeneration is a fundamental test for a 
potential AD therapy. 24 hours after incubation with 0.7mM GA and compound 16g 
at various concentrations, we have exploited confocal microscopy to investigate the 
neuronal morphology for the presence of any ameliorations. We found that compound 
16g treatment significantly prevented neurite shortening in a dose-dependent manner, 
and exhibited more potent improvement effects than Tideglusib at the same 
concentrations (Fig.30 A-C).   
Also, inhibition of both AChE and GSK3-β by compound 16g confirmed the positive 
trend by preventing neurite shortening in 1mM GA treated neurons as well, 



















Figure 30. Dose-dependent amelioration of neurite morphology by compound 16g in 
0.7mM GA exposed neurons 
A) Confocal images of SH-SY5Y-derived neurons under different treatment. B)  Neurite 
length quantification of 0.7mM GA treated SH-SY5Y differentiated neurons after 16g 
treatment. C) Neurite length quantification of 0.7mM GA treated SH-SY5Y differentiated 
neurons after Tideglusib treatment. Ordinary one-way ANOVA followed by Tukey’s post-hoc 
test was used to compare differences between different groups. Data is presented as mean ± 


















Figure 31.  Amelioration of neurite morphology by compound 16g in 1mM GA exposed 
neurons 
A) Confocal images of SH-SY5Y-derived neurons under different treatment. B)  Neurite 
length quantification of 1mM GA treated SH-SY5Y differentiated neurons after 16g treatment. 
C) Neurite length quantification of 1mM GA treated SH-SY5Y differentiated neurons after 
Tideglusib treatment. Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used 
to compare differences between different groups. Data is presented as mean ± SEM, n=3 with 




6.2.7 Increased cell viability following novel AChE inhibitor treatment  
Depletion of cholinergic neurons is a well-known characteristic of AD pathogenesis, 
with the major circuits involved in memory and learning functions, being represented 
by this type of neurons. In order to study whether inhibition of AChE enzyme would 
result in an increased cells viability after 0.7 or 1mM GA treatment an MTT assay was 
performed.  
In neurons treated with 0.7mM GA, all AChE inhibitors tested significantly prevented 
the dramatic cell death observed in untreated neurons, with the exception of compound 
FAD (Fig.32 A-E). On the other hand, XJP-1 showed no efficacy in preventing cell 
deaths in 1mM GA treated neurons, whilst SAD-2 and Donepezil successfully did with 
overlapping results (Fig.33 A-C). Moreover, AChE inhibitors SAD-6, and FAD, 




Figure 32. Cell viability quantification of 0.7mM GA exposed SH-SY5Y differentiated 
neurons after treatment with different AChE inhibitor 
A) MTT assay of SH-SY5Y differentiated neurons following 0.7mM GA treatment and 
compound XJP-1. B) MTT assay of SH-SY5Y differentiated neurons following 0.7mM GA 
treatment and compound Donepezil. C) MTT assay of SH-SY5Y differentiated neurons 
following 0.7mM GA treatment and compound SAD-2. D) MTT assay of SH-SY5Y 
differentiated neurons following 0.7mM GA treatment and compound SAD-6. E) MTT assay 
of SH-SY5Y differentiated neurons following 0.7mM GA treatment and compound FAD. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
differences between different groups. Data is presented as mean ± SEM, n=3 with at least 5 






Figure 33. Cell viability quantification of 1mM GA exposed SH-SY5Y differentiated 
neurons after treatment with different AChE inhibitors 
A) MTT assay of SH-SY5Y differentiated neurons following 1mM GA treatment and 
compound XJP-1. B) MTT assay of SH-SY5Y differentiated neurons following 1mM GA 
treatment and compound Donepezil. C) MTT assay of SH-SY5Y differentiated neurons 
following 1mM GA treatment and compound SAD-2. D) MTT assay of SH-SY5Y 
differentiated neurons following 1mM GA treatment and compound SAD-6. E) MTT assay of 
SH-SY5Y differentiated neurons following 1mM GA treatment and compound FAD. Ordinary 
one-way ANOVA followed by Tukey’s post-hoc test was used to compare differences between 
different groups. Data is presented as mean ± SEM, n=3 with at least 5 repetition per 




6.2.8 Compound 16g prevents neuronal cell death 
Neuronal cell death is the major issue of neurodegenerative diseases.  Since they do 
not actively replicate, once a neuron undergoes a programmed cell death it will not be 
replaced. Thus, prevention of neuronal cell death is a crucial point for a successful AD 
therapy, since NFTs are a potential cause of neuronal apoptosis.  
To investigate whether dual inhibition of both AChE and GSK3-β enzyme would 
result in preventing neuronal cell death, as a consequence of GA treatment, and 
subsequent Tau hyperphosphorylation, we assessed cells viability 24 hours after 
treatment administration. The presence of compounds 16g, as well as Tideglusib, 
showed neuroprotective effects by significantly increasing neurons viability, despite 
treatment with 0.7mM GA (Fig.32 A, B). Moreover, cell death was prevented in 
neurons treated with 1mM GA, suggesting that compound 16g as crucial 





Figure 34. Prevention of 0.7mM GA-induced cell death by compound 16g treatment 
A) MTT assay of SH-SY5Y differentiated neurons following 0.7mM GA treatment and 
compound 16g. B) MTT assay of SH-SY5Y differentiated neurons following 0.7mM GA 
treatment and compound Tideglusib. Ordinary one-way ANOVA followed by Tukey’s post-
hoc test was used to compare differences between different groups. Data is presented as mean 





Figure 35. Prevention of 1mM GA-induced cell death by compound 16g treatment 
A) MTT assay of SH-SY5Y differentiated neurons following 1mM GA treatment and 
compound 16g. B) MTT assay of SH-SY5Y differentiated neurons following 1mM GA 
treatment and compound Tideglusib. Ordinary one-way ANOVA followed by Tukey’s post-
hoc test was used to compare differences between different groups. Data is presented as mean 





6.2.9 Novel AChE inhibitors and dual AChE/GSK3-β inhibitor reduce 
AChE-induced amyloid aggregation rate 
Tau hyperphosphorylation and deposition of amyloid plaques are considered to be the 
two major players in AD pathogenesis.  
Since AChE enzyme function in promoting β-peptides aggregation, we investigated 
whether any of the novel compounds could decrease the aggregation rate by binding 
to AChE enzyme. All of the inhibitors tested showed a significant reduction of amyloid 
aggregation rate (Fig.36 A-F). In particular, dual AChE/GSK3-β inhibitor showed a 
significant reduction at a concentration as low as 50nM, with the same results being 
obtained by Donepezil, the most potent AD therapy approved by the FDA, at the same 
concentration (Fig.36 B, F).  
XJP-1, SAD-2, SAD-6, and FAD, confirmed the theory that inhibition of AChE 
enzyme is implicated in amyloid aggregation rate reduction, with almost all 




Figure 36. Reduction of amyloid peptides aggregation rate by inhibition of AChE enzyme 
AChE-induced amyloid aggregation Aβ-peptides aggregation rates in presence of AChE 
inhibitors: A) XJP-1. B) Donepezil C) SAD-2. D) SAD-6. E) FAD F) FAD. 
Ordinary one-way ANOVA followed by Tukey’s post-hoc test was used to compare 
differences between different groups. Data is presented as mean ± SEM, n=3 with at least 5 
repetition per experiment, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.  
 
6.3 Discussion 
In AD the regulation of multiple pathways involved in the pathogenesis and 
progression of the disease is the main target for a potential disease-modifying therapy. 
The novel compound 16g aims to do so by inhibiting both AChE enzyme and GSK3-
β, with its structure designed using Tacrine and Pyrimidone as models (Eagger et al. 
1991; Panza et al. 2016). In addition to this, the exploitation of a model that well 
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recapitulates AD neuronal features is an important step to better characterize newly 
synthesized compound for AD treatment. We have successfully combined two 
different protocols, in order to develop a neuronal model of AD Tau 
hyperphosphorylation (Shipley 2016; Koriyama et al. 2015). In particular, using GA 
to inhibit glycolysis, and increase AGEs level, well recapitulates the AD human 
features, in which accumulation of AGEs, and subsequent activation of RAGE 
receptor is often described, leading to activation of amyloidogenic pathway and Tau 
hyperphosphorylation (Deane et al. 2012; Donahue et al. 2006; Srikanth et al. 2011; 
Yan et al. 1996). Accumulation of AGEs as a consequence of GA treatment, results in 
Tau disease as seen in diabetes patients, which pathology is often linked to the 
development of AD (Kong et al. 2020; Batkulwar et al. 2018; Cai et al. 2016; Bitel et 
al. 2012). The model developed well recapitulates the neuronal features of AD, with 
GA treatment leading to abnormal phosphorylation of Tau protein on different 
residues, neurite degeneration, along with reduced cell viability.  
This model is of peculiar relevance as it offers, a novel platform to further study on 
RAGE signalling, which has often been linked to AD development (Li, Lv, et al. 
2012b).  RAGE is an immunoglobulin superfamily receptor capable of binding, AGEs, 
Amyloid beta, and other ligands.  
In a work involving both SH-SY5Y and hippocampal primary neurons, application of 
AGEs induced a dose-dependent increase on Tau hyperphosphorylation on multiple 
residues including S199, S396, S404 (Cai et al. 2016). These results overlap our 
findings obtained after GA treatment, showing an increase aberrant phosphorylation 
in Tau S199 and S396.    
 
 
Assessment of dual AChE/GSK3-β inhibitor 16g showed as well promising results, 
overlapping results obtained by the commercially available GSK3-β inhibitor 
Tideglusib. In addition to this, 16g showed a significant reduction of amyloid 
aggregation, suggesting a potential amelioration of amyloid-derived symptomatology 
as previously observed by other AChE  inhibitor. This is of peculiar importance as 
Tideglusib has already been tested as AD therapy, but failed during phase II clinical 
trial (Lovestone et al. 2015). Therefore, the simultaneous inhibition of AChE and 
GSK3-β may improve the efficacy on AD treatment, despite further test on amyloid-
related pathology are necessary to confirm this.  
 
On the other hand, among the different AChE inhibitors tested did not resulted in a 
homogenous comparable outcome, despite significant inhibition of the enzyme 
recorded, suggesting that inhibition of AChE enzyme may modulate different AD 
pathways involved in the Tau hyperphosphorylation triggered by GA, but in a non-
specific manner derived by the distribution and concentration of different 
acetylcholine receptors. Other than that, for several compounds a non-significant 
inhibition of AChE enzyme still resulted in a significant amelioration of the parameters 
analysed, further suggesting that inhibition of AChE enzyme result in a response 
controlled by the pathways activated by specific acetylcholine receptors. 
Despite this, inhibition of AChE enzyme was confirmed to reduce amyloid aggregation 
rate for all the compounds tested, further confirming the importance of AChE enzyme 




7 Final Discussion 
Amyloid plaques aggregation, presence of neurofibrillary tangles, and depletion of 
cholinergic neurons characterise the pathogenesis and progression of AD (Tiwari et 
al. 2019; Hampel et al. 2018). However, a clear causative agent is still missing 
resulting in a constant failure of AD clinical trial (Cummings et al. 2019).  
Several reports have highlighted as a triggering mechanism the depletion of 
cholinergic neurons in crucial memory and learning circuits, others reported the 
amyloid cascade as AD starting point, while different research groups focused on 
NFTs as potential causative agent (Zhang et al. 2020; Mi et al. 2006; Ramos-
Rodriguez et al. 2013).  
What is clear is that all these potential AD triggering mechanisms, and related 
pathways, are connected to each other, and which balance is disproportionate with 
aging, the main risk factor of AD, leading to symptoms exacerbation in the elderly 
population (Sala Frigerio et al. 2019). Thus, a therapy able to modulate multiple 
aspects of AD could potentially stop the disease progression. 
 
 In this research project, we have initially investigated the efficacy of a novel AChE 
inhibitor as AD therapy, as well as the currently FDA approved AChE inhibitors. 
AChE inhibitors are the first class of molecules approved by the FDA for AD 
treatment, aiming to increase the acetylcholine levels in those cholinergic network 
implicated in memory and learning functions (Nordberg et al. 1998). However, none 
of the current AChE inhibitors used for AD treatment has shown disease-modifying 
effects, with their benefit being limited to a stabilization of the psychiatric 
symptomatology (Haake et al. 2020; Wilkinson et al. 2004). Despite these limitations, 
AChE enzyme is still being used as AD target for its implications in the cognitive 
 
symptomatology, in amyloid plaques aggregation, and for the fact that many of the 
AChE inhibitors have a beneficial effects for a limited time. (dos Santos Picanco et al. 
2018; Inestrosa et al. 1996; Jiang et al. 2019; Rees et al. 2003; Shrivastava et al. 2019; 
Silman et al. 2008; Tayeb et al. 2012; Wang et al. 2015; Wang et al. 2018).  
 
As a result of our collaboration with Prof. Xu research team, we were able to test novel 
AChE inhibitors, along with a multi-target drug molecule named 16g. The latter is a 
dual AChE/GSK3-β enzymes inhibitor, aiming to both modulate the psychiatric 
symptomatology, along with reducing Tau phosphorylation levels and, therefore, 
prevent the formation of NFTs.  
GSK3-β is a an important kinase in Tau phosphorylation, as it is responsible of 
phosphorylating a number of different residues, and it is activated by various pathways 
involved in AD pathogenesis (Chong et al. 2012; Hernandez et al. 2013; Hooper et al. 
2008; Li, Lv, et al. 2012a).  
 
Several milestones were defined to better test the efficacy of these novel molecules. 
We firstly assessed the suitability of different Drosophila melanogaster AD models to 
study the efficacy of novel AChE inhibitors provided by Prof. Xu (CPU – Nanjing). 
These included defining measurable parameters, which could be used to assess the 
effect on the induced symptomatology, along with an evaluation of the AD features 
present in the CNS. 
Secondly, we have assessed the efficacy of the novel molecule XJP-1, along with the 
FDA approved AD therapy, on a transgenic Drosophila overexpressing Aβarc peptides 
and, then, on Tau model of Drosophila.  
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Thirdly, we have developed a neuron-like model of AD harbouring Tau 
hyperphosphorylation features as drug testing platform.  
Fourthly, we have assessed the efficacy of the new compound 16g on the novel neuron-
like model of AD.  
Our work further confirms the extensively reported limited efficacy of AChE 
inhibitors as AD therapy, with only beneficial effects on amyloid-defects. However, 
despite such limitation, AChE inhibitor have been an optimal starting point to improve 
our strategy to treat AD, with clear needs of targeting Tau hyperphosphorylation. This 
not only paved the way for a dual inhibiting strategy for both AChE and GSK3-β 
enzyme, but also highlighted the importance of a more detailed model to study this 
aspect of AD.  
 
7.1  Inhibition of AChE enzyme by XJP-1 results in amelioration of 
amyloid-induced symptomatology 
Activation of amyloidogenic pathway leads to secretion of Aβ peptides in the 
extracellular environment, where they aggregates to form senile plaques (Takahashi et 
al. 2017).  Despite a triggering mechanism of the amyloid cascade is yet to be 
discovered, according to the cholinergic hypothesis, a depletion in cholinergic markers 
such as acetylcholine, and acetyltransferase, anticipates the activation of the 
amylodogenic pathway. In addition to this, the NBM, source of main cortical 
cholinergic innervation undergoes a neurodegenerative process during AD 
progression, therefore resulting in memory and learning impairments (Mesulam 2013; 
Bowen et al. 1976). Moreover, test on cholinergic antagonist have resulted in AD-like 
cognitive symptoms, whilst agonist improved the psychiatric symptomatology 
(Drachman et al. 1974).  
 
Recent studies linked the cholinergic system to the exacerbation of amyloid pathology 
as well, showing that depletion of cholinergic neurons resulted in accumulation of 
amyloid plaques (Ramos-Rodriguez et al. 2013; Potter et al. 2011). Other than that, a 
clear involvement of AChE enzyme in promoting, and accelerating, amyloid 
aggregation was demonstrated, along with evidences of increased neurotoxicity of Aβ 
fibrils (Inestrosa et al. 1996; Bartolini et al. 2003; Inestrosa et al. 2008; Alvarez et al. 
1998). Furthermore, inhibition of AChE enzyme results in a lower amyloid 
aggregation rate, therefore limiting amyloid plaques formation (Jiang et al. 2019; 
Carvajal et al. 2011).  
Thus, inhibiting AChE enzyme has been the main target over the past three decades, 
with a number of inhibitors approved as AD treatment, despite limited beneficial 
effects reported (Wilkinson et al. 2004; Tayeb et al. 2012).  
 
As a result of our collaboration with Prof. Xu research group at CPU, we were provided 
with a newly synthesized AChE inhibitor, XJP-1, with a reported dual binding activity 
to both PAS and CAS sites of AChE enzyme, resulting in an increased specificity for 
AChE over BuChE, which inhibition is commonly known for resulting in potential 
side effects (Wang et al. 2015; Jiang et al. 2019).  In order to study the efficacy of 
novel compounds, we exploited Drosophila melanogaster overexpressing mutant APP 
as AD model. The Aβarc flies exhibited a severe symptomatology, recapitulating the 
human features, along with deposition of amyloid plaques within the brain.  
Administrated at 40µM concentration, XJP-1 increased the life expectancies and 
locomotive functions of Aβarc flies, with results being overlapped only by Donepezil 
despite this being administrated at 0.5mM.  
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CNS analysis for amyloid plaques deposition revealed that XJP-1 reduced the amyloid 
spots count as early as 10 days after commencing the treatment, in crucial regions for 
cognitive functions of Drosophila Melanogaster. Conversely, none of FDA therapies 
was able to have comparable results, despite administrated at a much higher 
concentrations.  
We further assessed the efficacy of XJP-1 on amyloid deposition after 20 days of 
treatment, which resulted in a significant drop, with the same results being scored by 
Donepezil only, the most potent AD therapy approved by the FDA.  
To understand whether the reduction of amyloid plaques observed in the CNS was a 
result of a reduced peptide quantity, we quantified the Aβ peptides in the fly heads, 
and found no differences between treated and untreated group at any of the time points 
examined.  
Thus, we speculated that AChE inhibition would result in a slower aggregation rate of 
amyloid peptides, as previously reported (Inestrosa et al. 1996; Rees et al. 2003). 
Investigation of amyloid aggregation rate showed a significant reduction in amyloid 
aggregation rate in presence of AChE and XJP-1, with a drop of about 80% being 
replicated only by Donepezil at 0.5mM concertation. In addition to this, we evaluated 
whether combination of NMDAR antagonist Memantine along with AChE inhibitor, 
XJP-1 or Donepezil, would result in any further beneficial effect on the amyloid-
induced defects. However, none of the combined therapies evaluated resulted in a 
significant improvement when compared to the monotherapy.   
Taken together, this data suggests that XJP-1 significantly ameliorates the amyloid-
induced symptomatology by reducing the amyloid aggregation, and plaques formation, 
by inhibiting AChE enzyme.  
 
 
7.2 Inhibition of AChE enzyme does not result in a clear anti-Tau effect 
AD is a complex neurodegenerative disease composed of multiple features acting 
together in driving its progression. Despite amyloid plaques play a fundamental role 
in inducing neuronal toxicity and subsequent symptomatology, Tau 
hyperphosphorylation and NFTs are known to be a crucial player in AD progression 
and pathogenesis (Bloom 2014; Tapia-Rojas et al. 2019). Tau hyperphosphorylation 
is a consequence of an aberrant activation of different kinases, and/or phosphatases, as 
a downstream effect of multiple pathways (Grundke-Iqbal et al. 1986; Hu et al. 2008; 
Cai et al. 2016; Mi et al. 2006; Busche et al. 2019; Iqbal et al. 2005; Zhang et al. 
2020).  
It was reported an involvement of the cholinergic network in Tau 
hyperphosphorylation pathways and, additionally, that inhibition of AChE enzyme 
could prevent activation of GSK3-β, a fundamental kinase involved in this process 
(Yoshiyama et al. 2010; Noh et al. 2009; Hampel et al. 2018).  
To investigate whether XJP-1 treatment would results in any beneficial effect against 
Tau pathology, we used a different Drosophila model, expressing human Tau 2N4R 
isoform to assess the compound efficacy, along with the FDA approved therapies.  
Tau fruit flies showed a significant reduction in the lifespan along with locomotive 
defects. The Tau flies treated with XJP-1 showed increment of the life expectancy, 
without any improvement of the locomotive functions, with none of the other therapies 
under investigation having better results than XJP-1. Particularly, Donepezil was 
reported to improve climbing activity on Tau Drosophila at 30µM dosage, but despite 




Analysis of CNS for Tau hyperphosphorylation on S396 residue revealed that none of 
compounds tested showed a significant reduction of the abnormal phosphorylation 
after both 10 and 20 days of therapy.  
Moreover, study on neurodegeneration exploiting the REP model induced by Tau 
expression, revealed that Donepezil was the only drug able to rescue the eye defects, 
whilst none of the other therapies did.  
Since contradictive results were generated by using Tau Drosophila as AD model, we 
decided to design and develop a neuron-like model to test the novel drug candidate by 
exploiting SH-SY5Y differentiation, and GA-induced Tau hyperphosphorylation on 
SH-SY5Y as previously reported (Shipley 2016; Koriyama et al. 2015).  
Analysis of neurite density resulted in a significant increment of SH-SY5Y cells 
treated with RA along with an increased neurite length. Subsequently, since GA was 
reported to induce Tau hyperphosphorylation in SH-SY5Y cells, we assessed whether 
this result could be replicated in differentiated neurons as well. Analysis of Tau 
residues S199 and S396 showed a significant increment of phosphorylation levels in 
neurons treated with either 0.7mM or 1mM GA. Confocal imaging showed a 
significant reduction of neurite length in GA treated neurons, along with neuronal 
death. These parameters were then exploited to test XJP-1 along with novel AChE 
inhibitors, provided by Prof. Xu, named SAD-2, SAD-6, and FAD. 
Assessment of the AChE inhibitors on Tau phosphorylation resulted in contradictive 
results on S199 with beneficial effects being recorded in 0.7mM GA exposed neurons, 
whilst no reduction was recorded in 1mM GA exposed neurons, despite AChE 
inhibition of the compounds tested showed overlapping results in both 0.7mM GA and 
1mM GA exposed neurons. On the other hand, all AChE inhibitors tested were able to 
 
reduce the phosphorylation levels on S396 in both 0.7mM GA and 1mM GA treated 
neurons.  
 
Morphology analysis to assess whether AChE inhibition would result in any 
prevention of neurite degeneration resulting from 0.7mM GA treatment and Tau 
hyperphosphorylation, showed positive results only in XJP-1 treated neurons, whilst 
none of the other AChE inhibitors showed a significant difference from the untreated 
group. 
Conversely, 1mM GA exposed neurons treated with AChE inhibitors recorded a 
significant increment of neurite length compared to the untreated group, with just 
Donepezil (at 5µM concentration) and SAD-6 (at 0.5µM) not recording a significant 
effect.  
 
Further to this, in order to investigate whether AChE inhibition effects on neuronal 
cell death induced by GA treatment and subsequent abnormal phosphorylation, we 
performed an MTT assay in 24hours treated cells. All AChE inhibitors tested showed 
a significant increase in cell viability in 0.7mM GA exposed neurons, with the 
exception of compound FAD. In 1mM GA exposed neurons XJP-1 administration did 
not result in a significant increase in cell viability, whilst FAD, which failed on the 
previous assay, significantly reduced cell death at 5µM concentration.  
In order to evaluate the ability of novel compounds in reducing the amyloid 
aggregation rate by inhibiting AChE enzyme, we  assessed the peptides aggregation in 
presence of the new inhibitors. All AChE inhibitors showed a significant reduction of 
the amyloid aggregation rate at various concentration, up to 10nM, confirming the 




To summarize, these data suggests that AChE inhibition can modulate Tau 
phosphorylation in an indirect manner. The variety, and often contradictive, results we 
obtained showed the limitation of the AChE inhibitor therapy, which outcome is not 
controlled by the drug mechanism itself, but rather from the composition of 
acetylcholine receptors in the post-synaptic neurons, which then trigger a number of 
different pathways not controlled by the AChE enzyme itself.  
 
7.3 Dual inhibition of GSK3-β and AChE enzymes modulates Tau 
phosphorylation in neuron-like model of AD and improves cognitive 
functions in mice 
GSK3-β is a long known kinase involved in a number of different functions. In AD it 
has been highlighted as fundamental kinase in Tau phosphorylation on multiple 
residues, as well as in the amyloidogenic pathway (Chu et al. 2017; Hernandez et al. 
2013; Hooper et al. 2008). GSK3-β is the downstream kinase activated by multiple 
different pathways, such as RAGE signalling pathway (Cai et al. 2016; Li, Lv, et al. 
2012b; Ramasamy et al. 2005; Takuma et al. 2009). The latter is activated as a result 
of AGEs accumulation, which is often described in diabetes patients and more 
frequently linked to AD development (Kong et al. 2020).  
Since GSK3-β is the downstream actor of multiple processes, targeting it with a 
pharmacological inhibitor could result in the prevention of Tau phosphorylation, and 
formation of NFTs.  
In order to target GSK3-β, Prof. Xu research group, kindly provided us with a novel 
dual AChE/GSK3-β inhibitor, named 16g, which we tested on the novel Tau model 
along with the commercial GSK3-β inhibitor Tideglusib as control drug. 
 
Compound 16g, showed a significant dose-dependent reduction of S199 
phosphorylation levels in neurons exposed to 0.7mM GA, at a concentration as low as 
50nM, whilst Tideglusib recorded a significant reduction only when administrated 
5µM. On the other hand, no significant reduction was recorded on 1mM GA exposed 
neurons treated with 16g, while Tideglusib showed a drop in phosphorylation levels 
in S199.  
Analysis of S396 residue revealed a significant reduction of phosphorylation levels on 
both 0.7mM and 1mM GA exposed neurons after treatment with either 16g or 
Tideglusib. 
In addition to this, 16g treatment prevented neurite degeneration in a dose-dependent 
manner in 0.7mM GA exposed neurons, with results being replicated by Tideglusib.  
Morphology analysis of 1mM exposed neurons incubated with compound 16g showed 
a significant increase in neurite length; again these results were confirmed by 
Tideglusib.  
Cell viability assessment after treatment with either 16g or control drug Tideglusib 
recorded a significant increment, at all concentration studied, in both 0.7mM and 1mM 
GA exposed neuron. 
Further to this, we decided to investigate 16g efficacy in inhibiting amyloid 
aggregation induced by AChE, since its reported dual inhibitory activity against both 
AChE and GSK3-β enzymes.  
Compound 16g significantly reduced amyloid aggregation in presence of AChE 
enzyme, at a concentration as low as 50nM, suggesting its potential in modulating 
amyloid aggregation as well.  
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Animal studies, performed by Prof. Xu and Dr. Pengfe Zhang at CPU, showed a 
significant improvement of the cognitive functions in an AD animal model as well 
(Fig.S4 A-C). 
 
To conclude, compound 16g multi-target strategy showed a homogenous effect in 
preventing GA-induced Tau hyperphosphorylation, with results being overlapped by 
a commercial GSK3-β inhibitor.  
The demonstrated efficacy in modulating Tau phosphorylation on multiple residues, 
along with the potential of reducing the amyloid aggregation rate, of compound 16g 




8 Final Conclusions 
The results presented in my PhD thesis suggest that inhibition of AChE enzyme can 
modulate multiple different pathways involved in AD pathogenesis, despite not being 
directly controlled by the therapy itself, giving a possible explanation for the often 
contradictive results observed when assessing different AChE inhibitors.  
However, a clear beneficial effect was found in modulating amyloid aggregation, and 
prevention of amyloid-induced symptoms.  
The development of a novel neuron-like model of AD harbours multiple benefits 
including:  reduced costs, Tau phosphorylation on multiple residues, possible platform 
to study diabetes and AD link. This model has allowed me to overcome the issue faced 
in the Drosophila model, in particular the uncontrolled dosage.  
 
In addition to this, the results obtained on the novel compound 16g suggests that it can 
modulate different aspects of the disease, which is of crucial importance for treating 
AD which has an unknown triggering mechanism. Thus, targeting a downstream 
enzyme such as GSK3-β, implicated in both Tau and amyloid pathways, along with 
modulation of psychiatric symptomatology, by AChE inhibition, can be a successful 
way of treating AD. 
 
9 Limitations and future perspectives 
There are several parts of the work described in this thesis that highlight the limitations 
of the model/results obtained, and potential area of further research to overcome them.  
One of the first limitation is the usage of Drosophila melanogaster as AD model. The 
fruit fly genotype we exploited recapitulates the human symptomatology and CNS 
features. However, it is a form of EOAD, which account for only the 1% of the total 
AD cases. Tests on a fruit fly genotype expressing human Tau 2N4R, BACE1 enzyme, 
and APP protein resulted in a shortened lifespan only, whilst no signs of locomotive 
defects, nor neurodegeneration were recorded. In addition to this, in order to 
administrate the drug to the AD flies, each compound was mixed within the food. 
Thus, there is no control over the actual amount of food/drug eaten by each fly. 
Moreover, the transgene expression was achieved using the Gal4/UAS system. The 
Gal4 gene expression was placed under the control of the genomic enhancer elav, 
resulting a pan-neuronal expression of the Aβ peptides. It is unlikely that, 
simultaneously, all neurons of an AD patient present an active amyloidogenic 
pathway.  
Future research on Drosophila AD models, should be focused on a  genotype able to 
include the human features described in LOAD, along with the definition of different 
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stages of AD to overcome the unrealistic method of treating AD Drosophila from day 
1 post eclosion.   
Unfortunately, there is no way to control how much each fly eat, leading to different 
flies being treated with diverse dosage. 
Another important limitation of Drosophila melanogaster as AD model is the lack of 
a BBB, which limits the reality of the data obtained on this particular in vivo model. 
The BBB is often identified as a crucial limitation in drug delivery strategies, as it 
limits the permeability to the majority of drug molecules. To overcome the limitations 
encountered using the Drosophila AD models, we decided to design and develop a 
neuronal model by combining two existing protocols currently used in SH-SY5Y cell 
line. However, the model we set up can be further improved. 
First, a comprehensive investigation of which pathways are activated following GA 
treatment should be performed. Despite reports of increase AGEs concentration, and 
potential activation of RAGE signalling, this should be elucidated in differentiated 
neurons as well. Moreover, the cell culture set up did not include microglia cells, which 
are a fundamental player in AD pathogenesis. Further to this, the 2D cell culture set 
up can biased by the fact that neurons do not form a proper 3D network.   
An investigation on the pathways activated by GA, along with a 3D set up of the cell 
culture would benefit this type of model. Other than that, electrophysiology studies on 
neuron treated with GA, and compounds, can be useful to enhance the understanding 
of AD and better characterise the therapy effects.  
A further limitation of this work is the fact that all data about drug efficacy was 
obtained on models recapitulating one feature of AD, such as amyloid plaques and 
hyperphosphorylated Tau. This is a major concern, since AD pathogenesis is 
composed of an array of different pathways, involving not only amyloid plaques and 
 
NFTs. Thus, drug screenings should be performed on the most realistic model of AD 
which recapitulates all features observed in human patients. This would benefit not 
only the outcome data, which would be more realistic, but also the chances of success 
of a potential clinical trial.  
Despite a number of limitation can be highlighted, this novel cell culture AD model 
offers the possibility of further optimization and research. First, Crispr/Cas9 
technology can be used to knockout selective genes in order to model multiple aspects 
of AD. For instance, by inserting a point mutation on APP gene the Aβ peptides 
deposition can be triggered offering the possibility to study both amyloid and Tau 
pathology in the same dish. Secondly, the model itself can be used to evaluate the 
whether GA application causes an amyloidogenic cleavage of APP, as a result of 
GSK3-β activation (Llorens-Martín et al. 2014). Thus, we believe that the novelty of 
this model, offers the possibility of further dissecting several aspects of AD 
pathogenesis, and a testing platform for novel drug candidates.   
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Supplementary figure 1. Dosage screening 
A) Kaplan-Meier survival trajectories of AβArc flies under Donepezil treatment at different 
dosage. B) Mean survival time of AβArc flies under Donepezil treatment at different dosage. 
C) Kaplan-Meier survival trajectories of AβArc flies under XJP-1 treatment at different dosage. 
D) Mean survival time of AβArc flies under XJP-1 treatment at different dosage. 
Kuskar-Wallis test followed by Dunn’s post-hoc was used to compare the differences between 
different groups. Data are expressed as mean ± SEM, n = 3. P<0.05 was considered as 























Supplementary figure 2. Comparisons between combined therapies and monotherapies 
on Aβarc flies 
 A) Survival time comparison B) Comparison of CNS amyloid spots count after 10 days. C) 
Comparison of CNS amyloid spots count after 20 days.  D) Comparison of Mushrooms bodies 
and fan-shaped bodies amyloid spots count after 10 days.  E) Comparison of Medulla and 
Optic Lobes amyloid spots count after 10 days. F) Comparison of Mushrooms bodies and fan-
shaped bodies amyloid spots count after 20 days. G) Comparison of Medulla and Optic Lobes 
amyloid spots count after 20 days. Data are presented as mean ± SEM, of n = 3 P<0.05 was 


















Supplementary figure 3. Amyloid peptides quantity in Aβarc flies’ heads 
A) Representative images of WB membranes showing amyloid peptides quantity after 10 days 
of treatment. B) Day-10 AβArc peptide quantification by membrane image analysis. C)  
Representative images of WB membranes showing amyloid peptides quantity after 20 days of 
treatment. D) Day-20 AβArc peptide quantification by membrane image analysis. ANOVA test 
followed by Bonferroni’s post-hoc was used to compare the differences between different 
groups. Data are presented as mean ± SEM, n = 3. P<0.05 was considered as significant. * 

















Supplementary figure 4. Effects of compound 16g on scopolamine treated mice  
Effects of intraperitoneal administration of 16g (15 mg/kg), 23e (15 mg/kg), and Tacrine (4, 
15 mg/kg) on scopolamine-induced cognitive impairment in ICR mice evaluated by the Morris 
water maze test. A) Latency to first entry.  B) Distance to first entry. C) Entering time. . Data 
are presented as the mean ± SEM (n = 8; #p ≤ 0.05, ##p ≤ 0.01 vs blank control group; *p ≤ 
0.05, **p ≤ 0.01 vs scopolamine group). This image and caption are courtesy of Prof. Jinyi Xu 
and Dr. Pengfei Zhang of CPU. The data presented in this image is the result of work carried 
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